Killexams.com A00-281 Q&A are best to Pass exam | | Inicio RADIONAVES

Killexams.com A00-281 exam simulator is the best prep tool ever made It uses updated - - and to best prepare for the test - - Inicio RADIONAVES

Pass4sure A00-281 dumps | Killexams.com A00-281 real questions | http://www.radionaves.com/

A00-281 Clinical Trials Programming Using SAS 9 Accelerated Version

Study usher Prepared by Killexams.com SASInstitute Dumps Experts


Killexams.com A00-281 Dumps and real Questions

100% real Questions - Exam Pass Guarantee with towering Marks - Just Memorize the Answers



A00-281 exam Dumps Source : Clinical Trials Programming Using SAS 9 Accelerated Version

Test Code : A00-281
Test title : Clinical Trials Programming Using SAS 9 Accelerated Version
Vendor title : SASInstitute
: 99 real Questions

save your money and time, rob those A00-281 and prepare the examination.
a few extraordinary tidings is that I passed A00-281 rob a spy at the day before today... I thank complete killexams.com group. I surely prize the first-rate work which you replete do... Your training material is super. maintain doing preempt work. i will really exhaust your product for my subsequent examination. Regards, Emma from the spacious apple


Do you want modern-day dumps modern-day A00-281 examination to pass the exam?
A00-281 QAs bask in stored my life. I didnt sense assured in this region and Im satisfied a chum has informed about killexams.com SASInstitute package with me some days before the exam. I want id buy earlier, itd bask in made things much easier. i thought that I passed this A00-281 exam very early.


located A00-281 real question source.
I had taken the A00-281 practise from the killexams.com as that turned into a nice platform for the education and that had in the conclude given me the satisfactory degree of the education to assemble the first-class scores inside the A00-281 test tests. I genuinely enjoyed the manner I were given the matters completed in the lunimous way and via the lighten of the equal; I had sooner or later were given the issue on the line. It had made my instruction tons less complicated and with the assistof the killexams.com I had been capable of grow nicely in the life.


Little effor, spacious output, remarkable questions and answers.
They fee me for A00-281 exam simulator and QA document however first i did no longer got the A00-281 QA material. there has been some file blunders, later they constant the error. i organized with the examination simulator and it changed intoproperly.


How a remarkable deal does it cost A00-281 qustions bank with actual dumps
its far exceptional! I surpassed my A00-281 examination the day prior to this with a nearly best score of 98%. thank youKillexams! The substances in the package are genuine and legitimate - that is what I were given on my other examination. I knew answers to most of the questions, and some extra questions were very similar and on the topics absolutelycovered inside the rob a spy at guide, so i used to be capable of solution them on my own. no longer best did i am getting an top notch getting to know device which has helped me expand my professional knowledge, but I besides receivedan smooth bypass to my A00-281 certification.


simply attempt those dumps and success is yours.
The association time for A00-281 examination was clearly a pleasant taste for me. Effectively passing, I actually bask in establish out a way to transparent replete of the in addition degrees. Because of killexams.Com Questions & Answers for replete the assistance. I had restrained time for readiness but killexams.Com brain dumps became out to be a lighten for me. It had sizable question and answers that made me design in a brief compass.


Is there a shortcut to speedy prepare and pass A00-281 examination?
The modish of killexams.Com is towering enough to lighten the applicants in A00-281 exam schooling. replete the goods that I had used for A00-281 exam instruction bask in been of the first-rate best so that they assisted me to immaculate the A00-281 exam shortly.


I want actual examination questions today's A00-281 examination.
its far about unique A00-281 examination. i bought this A00-281 braindump before I heard of supplant so I thought I had spent cashon something i would no longer be able to use. I contacted killexams.com support team of workers to double rob a spy at, and they advised me the A00-281 exam were updated these days. As I checked it against the ultra-modern A00-281 exam goalsit honestly seems up to date. a number of questions bask in been added compared to older braindumps and replete regionsprotected. Im impressed with their performance and customer support. searching ahead to taking my A00-281 exam in 2 weeks.


first rate possibility to assemble certified A00-281 examination.
My friends told me I could count on killexams.com for A00-281 exam preparation, and this time I did. The brain dumps are very convenient to use, I cherish how they are set up. The question order helps you memorize things better. I passed with 89% marks.


labored hard on A00-281 books, however the complete thing changed into in the .
Hi, I had sign up for A00-281. Even though I had study replete chapters substantial, but your question pecuniary institution provided sufficient training. I cleared this exam with 99 % yesterday, thanks plenty for to the element question bank. Even my doubts bask in been clarified in minimum time. I necessity to exhaust your service in destiny as nicely. You men are doing a tremendous process. Thank you and Regards.


SASInstitute SASInstitute Clinical Trials Programming

E-scientific Trial technologies - global Strategic company report 2015-2020: Surging SaaS-primarily based options within the eClinical landscape | killexams.com real Questions and Pass4sure dumps

March 25, 2015 06:17 ET | source: research and Markets

Dublin, March 25, 2015 (GLOBE NEWSWIRE) -- research and Markets (http://www.researchandmarkets.com/research/wjjlm8/eclinical_trial) has announced the addition of the "E-scientific Trial applied sciences - world Strategic industry record" document to their providing.

Annual estimates and forecasts are supplied for the duration 2013 via 2020. additionally, a 3-year ancient analysis is equipped for these markets. Market statistics and analytics are derived from basic and secondary analysis. enterprise profiles are basically in keeping with public domain tips together with industry URLs.

This document analyzes the global markets for E-scientific Trial technologies in US$ Million by the following Segments:

  • electronic facts capture (EDC) solutions
  • medical Trial management gadget (CTMS)
  • digital affected person pronounced influence (ePRO)
  • Randomization and Trial provide administration (RTSM)
  • The file profiles 85 corporations together with many key and area of interest avid gamers comparable to:

  • Almac neighborhood (UK)
  • ArisGlobal LLC (US)
  • BioClinica (US)
  • Clinipace worldwide (US)
  • Cmed know-how Ltd (UK)
  • DATATRAK foreign, Inc. (US)
  • DSG Inc. (US)
  • DZS software solutions, Inc. (US)
  • eClinForce, Inc (US)
  • eClinical Insights, Inc. (US)
  • eResearch technology, Inc. (US)
  • integrated scientific solutions, Inc. (US)
  • Medidata options, Inc. (US)
  • MedNet solutions (US)
  • Merge Healthcare, Inc. (US)
  • Nextrials Inc. (US)
  • OmniComm methods, Inc. (US)
  • Oracle fitness Sciences (US)
  • PAREXEL international Corp. (US)
  • Perceptive Informatics, Inc. (US)
  • PHT Corp. (US)
  • Prelude Dynamics LLC (US)
  • SAS Institute Inc. (US)
  • target fitness Inc. (US)
  • Trianz options (US)
  • Key issues lined:

    1. industry OVERVIEW

  • A Prelude
  • impact of Healthcare cost range Cuts: A Retrospective evaluate
  • Market Outlook
  • Market Gravitates from Developed countries to setting up international locations
  • Outsourcing of medical reports to establishing countries merits Market
  • Globalization Boosts e-scientific Trials Market
  • Regulatory Acceptance of digital Submissions: a crucial growth Driver
  • charge-Containment: a crucial component increasing the Uptake of E-scientific Trial technologies
  • Sponsor Consolidation Brings forth the desultory of competitors
  • Governmental laws desultory the Requirement of expensive changes to know-how
  • 2. MARKET DYNAMICS

  • EDC side Witnesses Upward trend
  • components influencing EDC selection
  • vendors music listing
  • Regulatory Compliance
  • records safety specifications
  • Product and repair expenditures
  • tablet-layout records seize devices to profit Traction within the EDC Market
  • Tangible cost -savings Bolster swift Uptake of CTMS solutions
  • select fundamental scientific Trial administration programs (CTMS) providers worldwide
  • Rising number of side IV Trials Accentuates role of CTMS
  • electronic affected person record (ePRO) options swiftly replacing Paper-based mostly pro techniques
  • option Grows for customized/Configured RTSM
  • RTSM techniques with Self-service Capabilities to Displace typical IVR/IWR software
  • Multifarious Operational merits pressure IVRS Adoption
  • Globalization of medical Trials Throws Up Challenges for IVR/IWR outfit developers
  • Integration of Standalone eClinical techniques: want of the Hour
  • becoming summon for Integration of EDC with CTMS and ePRO systems
  • integrated EDC-RTSM programs - the unique Paradigm
  • subsequent era e-scientific systems aid existence Sciences agencies face unique Challenges
  • Open source - emerging solutions in scientific Trials domain
  • select Open source technologies for medical Trials by way of utility enviornment
  • benefits over Proprietary applied sciences to inspire Adoption
  • EDC- the most fascinating software for Open source
  • Conversion to CDISC - An rising utility for Open supply options
  • mobile applied sciences to lighten Trial Operators in Tackling Challenges
  • Smartphones & pills: the unique Age ePRO devices
  • Surging SaaS-based options within the eClinical panorama
  • web-based outfit for Enrolment Modeling and Planning
  • A Peek into different inventive applied sciences
  • software solutions for capacity Planning and Forecasting
  • a Noteworthy know-how in the Offing
  • three. aggressive panorama

  • Oracle Dominates the eClinical Trial options space
  • opt for main gamers in eClinical applied sciences
  • Oracle's Acquisition Spree Heats up competitors
  • competitors in EDC Market: An insight
  • A Fragmented business
  • competitive factors
  • choose Key players in the CTMS Market
  • photograph of pick CTMS solutions
  • four. PRODUCT PROFILE

  • Defining E-medical Trials
  • advantages offered by E-clinical Trials
  • Transparency
  • Dynamic software administration
  • constructive Trial Drug provide
  • advantageous examine Randomization
  • enhanced Collaboration
  • Dynamic website administration
  • less common Investigational site Visits
  • faster fade No-Go decisions
  • more suitable Planning
  • Regulatory Compliance
  • CDISC standards
  • clinical Trials- In a Nutshell
  • Summarization of medical Trial Phases & Time Line for Drug building
  • techniques utilized in E-scientific Trials
  • digital information ensnare solutions (EDC)
  • benefits of EDC
  • EDC and Paper CRFs - A assessment
  • fresh developments in EDC
  • clinical Trial management outfit (CTMS)
  • CDMS to CTMS: The Evolutionary stream to eDevelopment
  • CROs - The focused customers for CTMS
  • scientific Trial photo administration device (CTMS)
  • electronic affected person pronounced influence (ePRO)
  • electronic Diaries
  • Randomization and Trial deliver administration (RTSM)
  • Interactive Voice Response methods (IVRS)
  • technologies utilized in IVR
  • Interactive net Response programs (IWRS)
  • 5. PRODUCT/provider INTRODUCTIONS

  • Parexel Releases newest edition of ClinPhone RTSM
  • OmniComm unencumber of TrialOne version 4.three
  • Techorizon Launches Th-eClinical
  • ArisGlobal Releases agCapture version three.2
  • ArisGlobal Unveils agVet Pharmacovigilance solution
  • Surrey scientific analysis Centre Inks 5-year contract for OmniComm's Promasys
  • PHT enterprise Introduces LogPad® device on Google Nexus Smartphone
  • ArisGlobal Introduces agInquirer 3.1
  • eClinical Insights Unveils eClinical Intelligence Platform
  • OmniComm methods, Inc. Introduces TrialMaster EDC edition four.2
  • Perceptive Introduces superior version of impact® CTMS answer
  • CluePoint Unveils wise Engine chance-based Monitoring answer
  • ArisGlobal Introduces agDisclosure three.1 solution
  • Clinipace worldwide Improves TEMPO eClinical Platform
  • Phoenix utility alien Unveils Entrypoint i4 EDC application
  • CRF health Unveils TrialMax® Suite eCOA utility with Android support
  • OpenClinica Unveils version three.1.three of OpenClinica enterprise edition
  • ePharmaSolutions Introduces PatientLive App for home windows 8 Platform
  • forte analysis incorporates Submission Console in OnCore® CRMS
  • Veeva programs Introduces Vault eTMF Cloud-based application
  • MedNet solutions Introduces unique version of iMedNet EDC software
  • Michigan Institute Unveils Mi-OC edition of OpenClinica CTMS
  • MonitorForHire.com Unveils unique cellular-based mostly software
  • PHT Introduces NetPRO 1.3 solution
  • ERT Unveils Upgraded clinical analysis Workflow expertise
  • Anoto community, Ubisys and Perinatal Institute develop E-Preginfo Maternity EDC system
  • Formedix Releases transform Suite for Perceptive's DataLabs EDC programs
  • OmniComm methods Unveils TrialMaster edition four.1.2
  • Techsol Introduces QuickLaunch LabPas Deployment package
  • Syne Qua Non Unveils unique version of Syne-clin® device
  • PAREXEL alien Introduces PAREXEL MyTrials Platform
  • Merge Healthcare Rolls Out Merge eClinical OS
  • Y-leading applied sciences Introduces top publisher Concatenation device
  • Nextrials to Unveil iPad software for Prism medical Trial administration Platform
  • IMS fitness Introduces IMS SiteOptimizer
  • specialty analysis programs Introduces OnCore® edition 12.0 CRMS
  • MedPoint Digital Launches cell friendly eClinical technologies
  • Lilly Oncology Introduces scientific Trial useful resource cell software
  • PharmaPros Unveils accommodate imperative Hybrid answer
  • PHT Launches edition four.16 of StudyWorks
  • Perceptive Informatics Unveils site inventory management Module for ClinPhone RTSM
  • Oracle fitness Sciences Unveils unique edition of clinical construction Analytics
  • Y-best applied sciences Rolls Out prime IxR and prime eMVR methods
  • Trianz options Unveils Acceliant eClinical Suite-v6.4
  • distinctiveness analysis techniques Unveils unique edition of Allegro CTMS@website
  • DATATRAK overseas Unveils uCTMS scientific Trial administration system
  • Synteract Launches SynCapture EDC outfit in edition 1.5
  • 6. fresh trade endeavor

  • BioClinica Takes Over Blueprint scientific, Inc.
  • Cliantha analysis Takes Over Karmic Lifesciences
  • Eurotrials companions Merge eClinical for medical analysis know-how
  • Instem and Medidata solutions to integrate Medidata Rave and ALPHADAS
  • Clinverse partners with eClinical Insights
  • TFS alien Selects OmniComm TrialMaster
  • JLL partners Takes Over CoreLab partners and BioClinica
  • CROS NT Takes Over Symphony EDC system from Powertrial
  • PharmaPros Renamed as eClinical Insights
  • SGS existence Science functions Selects Merge eCLINICAL OS for side I-IV stories
  • Tampa frequent medical institution Adopts Merge Healthcare CTMS
  • SIRO Clinpharm Deploys Oracle fitness Sciences InForm
  • OmniComm programs companions Soltex Consulting
  • Oracle Takes Over ClearTrial
  • Clinipace worldwide Merges with paragon Biomedical to acquire Irvine
  • eResearch technology Acquires Invivodata
  • IMS fitness Takes Over DecisionView
  • NTT statistics Secures DATATRAK Non-exclusive License for Reselling DATATRAK ONE
  • Larix signs settlement with OmniComm programs for eClinical Suite
  • QED medical functions Selects SimpleCTMS for Trial by using fire solutions
  • Veeva methods and Medidata options Collaborate for integrated Vault eTMF solution
  • NextDocs and BioClinica Enter into Partnership
  • Merge Healthcare and AG Mednet Enter into Partnership
  • Eclinso and XClinical Ink Strategic Partnership agreement
  • NCGS Chooses Merge Healthcare's eClinical OS and CTMS
  • international medical Trials Selects TransPerfect eTMF
  • TauRx Therapeutics Inks Agreements with BioClinica
  • advanced scientific Joins iMedNet colleague software of MedNet options
  • Tigermed Consulting Chooses Merge Healthcare CTMS
  • Datapharm Australia Chooses Merge Healthcare's eClinical OS
  • Kaketsuken Deploys Medidata solutions' Rave® and stability RTMS
  • Sanofi Selects BioClinica OnPoint CTMS
  • Isis prescribed drugs to lengthen exhaust of BioClinica's express EDC for Upcoming Trials
  • worldwide scientific Trials Chooses eClinical OS system from Merge Healthcare
  • TFS international Deploys Medidata CTMS from Medidata options global
  • Luitpold prescribed drugs Selects express EDC from BioClinic
  • Cytochroma Chooses Suite of applications from methods
  • TriReme clinical Chooses OpenClinica industry version
  • UCL scientific Trials Unit Selects MACRO EDC solution from InferMed
  • CHDI groundwork to set up eClinical GPS Platform and ClinCard gadget
  • INC research Chooses Trial Interactive eTMF from TransPerfect
  • PRC medical Selects SimpleCTMS from Trial by means of hearth options
  • TKL research Selects Medidata CTMS
  • Grünenthal Inks License settlement with BioClinica
  • Amarin Selects eClinical Suite of BioClinica
  • OmniComm methods Secures License for Pharma Medica's TrialMaster Suite
  • Harrison medical analysis Chooses BioClinica OnPoint CTMS
  • Greenphire Enters into Strategic Partnership with Merge Healthcare
  • 7. focal point ON pick avid gamers

    eight. world MARKET point of view

    complete groups Profiled: 85 (together with Divisions/Subsidiaries - ninety two)

  • the united states (fifty eight)
  • Canada (2)
  • Japan (1)
  • Europe (27)
  • - France (2)
  • - Germany (three)
  • - the United Kingdom (12)
  • - Italy (2)
  • - relaxation of Europe (8)
  • Asia-Pacific (apart from Japan) (4)
  • For extra assistance discuss with http://www.researchandmarkets.com/analysis/wjjlm8/eclinical_trial

    CONTACT: research and Markets Laura wood, Senior manager press@researchandmarkets.com For E.S.T workplace Hours title 1-917-300-0470 For U.S./CAN Toll Free summon 1-800-526-8630 For GMT workplace Hours title +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: medical Trials CONTACT: research and Markets Laura wood, Senior supervisor press@researchandmarkets.com For E.S.T workplace Hours summon 1-917-300-0470 For U.S./CAN Toll Free summon 1-800-526-8630 For GMT office Hours title +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outdoor U.S.): +353-1-481-1716 Sector: medical Trials 22157.jpg

    codecs available:


    recognize about the global built-in E-medical Trial Suites Market evaluation by way of regions, type, application, Market Drivers, Restraints Forecasts to 2023 | killexams.com real Questions and Pass4sure dumps

    long island, the spacious apple -- (SBWIRE) -- 09/14/2018 -- This record titled as built-in E-clinical Trial Suites, offers a quick concerning the finished analysis and an overview of its growth available in the market globally. It states the tremendous market drivers, traits, limitations and alternatives to give wide-ranging and precise statistics and besides scrutinizes its expand within the overall markets development, which is required and anticipated. additionally, it analyzes the sides that distresses the market globally, to extra do an acceptable preference on its dissection.

    This research resolve gives a sneak-peak through the summary which includes of overall facts reminiscent of, segments, sub-segments, information images, charts, tables and diagrams. The analysis additionally helps in probing the integrated E-scientific Trial Suites in its forecast duration. The resolve explores and estimates the modest panorama, generic company models and the obvious innovations in choices via major gamers within the coming years.

    Get sample reproduction of this document: https://www.researchnreports.com/request_sample.php?identity=223737

    Key avid gamers:Oracle fitness Sciences, BioClinica, eResearch know-how, Inc., Clinipace international,SAS Institute, Inc., MedidataSolutions, Datatrak foreign, Inc.and ParexelInternational agency.

    On the geographical entrance, the global market is categorised into Europe, Asia-Pacific, core East & Africa, North the us, and Latin the united states. The main vicinity of this international market and the region which is projected to proceed its dominance over the approaching years is given in the spy at. the key riding coerce behind the expand of this market in the near future is besides offered.

    Get deal on this file: https://www.researchnreports.com/ask_for_discount.php?identity=223737

    The document analyzes the complete claim and supply chain within the international built-in E-scientific Trial Suites market and stories the a number of add-ons. The impact of Porter's 5 forces on the growth of the market has been besides analyzed in the file. regarding case experiences, the document traces the historic building of the market. The claim for each of the product forms has been assessed within the report.

    extra, the essential thing geographical segments of the world built-in E-scientific Trial Suites market bask in been deliberated in the analysis study. the essential thing components which are enhancing the growth of the key segments bask in been provided within the examine. a thorough examine of the aggressive panorama of the global integrated E-clinical Trial Suites market bask in been given, presenting insights into the industry profiles, fiscal fame, coincident traits, mergers and acquisitions, and the SWOT evaluation. This research will supply a transparent thought to the readers about the usual market state of affairs to further pick this market project.

    table of Contents:

    global built-in E-clinical Trial Suites Market analysis document 2018-2023

    Chapter 1 built-in E-medical Trial Suites Market OverviewChapter 2 world pecuniary ImpactChapter 3 competition by using ManufacturersChapter four construction, revenue (price) by using vicinity (2018-2023)Chapter 5 give (production), Consumption, Export, Import by using areas (2018-2023)Chapter 6 construction, revenue (value), fee vogue by TypeChapter 7 analysis via ApplicationChapter 8 Manufacturing permeate AnalysisChapter 9 Industrial Chain, Sourcing routine and Downstream BuyersChapter 10 marketing routine analysis, Distributors/TradersChapter 11 Market impact factors AnalysisChapter 12 Market Forecast (2018-2023)Chapter 13 Appendix

    Get comprehensive record@: https://www.researchnreports.com/healthcare-it/world-integrated-E-scientific-Trial-Suites-Market-research-file-2018-2023-223737


    Air pollution and Mortality within the Medicare inhabitants | killexams.com real Questions and Pass4sure dumps

  • 1. Ambient (out of doors) air pleasant and health. fact sheet no. 313. up to date March 2014. Geneva: World fitness company, 2015.

  • 2. Brook RD, Rajagopalan S, Pope CA III, et al. Particulate count number air toxins and cardiovascular disease: an supplant to the scientific statement from the American coronary heart association. Circulation 2010;121:2331-2378

  • three. Lim SS, Vos T, Flaxman advert, et al. A comparative desultory assessment of cross of ailment and injury because of sixty seven risk elements and desultory component clusters in 21 areas, 1990-2010: a systematic analysis for the world cross of disease resolve 2010. Lancet 2012;380:2224-2260

  • four. Crouse DL, Peters PA, Hystad P, et al. Ambient PM2.5, O3, and NO2₂ exposures and associations with mortality over sixteen years of follow-up within the Canadian Census health and atmosphere Cohort (CanCHEC). Environ fitness Perspect 2015;123:1180-1186

  • 5. Wang Y, Kloog I, Coull BA, Kosheleva A, Zanobetti A, Schwartz JD. Estimating causal consequences of lengthy-term PM2.5 publicity on mortality in unique Jersey. Environ fitness Perspect 2016;124:1182-1188

  • 6. Beelen R, Raaschou-Nielsen O, Stafoggia M, et al. effects of long-time age exposure to air pollution on herbal-cause mortality: an analysis of 22 European cohorts in the multicentre assemble away undertaking. Lancet 2014;383:785-795

  • 7. Atkinson RW, Butland BK, Dimitroulopoulou C, et al. lengthy-term exposure to ambient ozone and mortality: a quantitative systematic evaluation and meta-evaluation of evidence from cohort stories. BMJ Open 2016;6:e009493-e009493

  • 8. Hao Y, Balluz L, Strosnider H, Wen XJ, Li C, Qualters JR. Ozone, nice particulate depend, and continual reduce respiratory disorder mortality in the united states. Am J Respir Crit permeate Med 2015;192:337-341

  • 9. Turner MC, Jerrett M, Pope CA III, et al. lengthy-time age ozone publicity and mortality in a big potential analyze. Am J Respir Crit permeate Med 2016;193:1134-1142

  • 10. Jerrett M, Burnett RT, Pope CA III, et al. lengthy-time age ozone publicity and mortality. N Engl J Med 2009;360:1085-1095

  • eleven. Krewski D, Jerrett M, Burnett RT, et al. extended follow-up and spatial analysis of the American melanoma Society spy at linking particulate air toxins and mortality. Res Rep fitness Eff Inst 2009;a hundred and forty:5-114, discussion a hundred and fifteen-136

  • 12. Carey IM, Atkinson RW, Kent AJ, van Staa T, prepare dinner DG, Anderson HR. Mortality associations with long-term publicity to out of doors air pollutants in a country wide English cohort. Am J Respir Crit permeate Med 2013;187:1226-1233

  • 13. Ostro B, Hu J, Goldberg D, et al. Associations of mortality with lengthy-time age exposures to first-class and ultrafine particles, species and sources: consequences from the California academics study Cohort. Environ health Perspect 2015;123:549-556

  • 14. Crouse DL, Peters PA, van Donkelaar A, et al. risk of nonaccidental and cardiovascular mortality on the subject of long-term publicity to low concentrations of first-rate particulate matter: a Canadian national-degree cohort analyze. Environ fitness Perspect 2012;a hundred and twenty:708-714

  • 15. Wang Y, Shi L, Lee M, et al. lengthy-time age publicity to PM2.5 and mortality among older adults within the southeastern US. Epidemiology 2017;28:207-214

  • sixteen. Thurston GD, Ahn J, Cromar KR, et al. Ambient particulate trust air pollution publicity and mortality within the NIH-AARP weight loss program and health cohort. Environ fitness Perspect 2016;124:484-490

  • 17. Pinault L, Tjepkema M, Crouse DL, et al. desultory estimates of mortality attributed to low concentrations of ambient first-rate particulate recall within the Canadian neighborhood health Survey cohort. Environ fitness 2016;15:18-18

  • 18. Shi L, Zanobetti A, Kloog I, et al. Low-attention PM2.5 and mortality: estimating acute and confirmed effects in a population-based analyze. Environ fitness Perspect 2016;124:forty six-fifty two

  • 19. Di Q, Kloog I, Koutrakis P, Lyapustin A, Wang Y, Schwartz J. Assessing PM2.5 exposures with excessive spatiotemporal resolution throughout the continental united states. Environ Sci Technol 2016;50:4712-4721

  • 20. Di Q, Rowland S, Koutrakis P, Schwartz J. A hybrid mannequin for spatially and temporally resolved ozone exposures in the continental united states. J Air Waste Manag Assoc 2017;67:39-52

  • 21. Kalnay E, Kanamitsu M, Kistler R, et al. The NCEP/NCAR forty-year Reanalysis assignment. Bull Am Meteorol Soc 1996;seventy seven:437-471

  • 22. Lee EW, Wei L, Amato DA, Leurgans S. Cox-classification regression analysis for spacious numbers of small corporations of correlated failure time observations. In: Klein JP, Goel PK, eds. Survival analysis: state of the art. Berlin: Springer, 1992:237-forty seven.

  • 23. Makar M, Antonelli J, Di Q, Cutler D, Schwartz J, Dominici F. Estimating the causal outcome of low stages of nice particulate matter on hospitalization. Epidemiology, may additionally 25, 2017 (http://journals.lww.com/epidem/summary/publishahead/Estimating_the_Causal_Effect_of_Low_Levels_of_Fine.98844.aspx).

  • 24. Kioumourtzoglou MA, Schwartz J, James P, Dominici F, Zanobetti A. PM2.5 and mortality in 207 US cities: modification by using temperature and city features. Epidemiology 2016;27:221-227

  • 25. Dockery DW, Pope CA III, Xu X, et al. An association between air pollution and mortality in six U.S. cities. N Engl J Med 1993;329:1753-1759

  • 26. Lepeule J, encumbered F, Dockery D, Schwartz J. persistent publicity to remarkable particles and mortality: an extended observe-up of the Harvard Six Cities study from 1974 to 2009. Environ fitness Perspect 2012;a hundred and twenty:965-970

  • 27. Pope CA III, Burnett RT, Thurston GD, et al. Cardiovascular mortality and long-term publicity to particulate air pollutants: epidemiological evidence of ordinary pathophysiological pathways of ailment. Circulation 2004;109:71-77

  • 28. Eftim SE, Samet JM, Janes H, McDermott A, Dominici F. exceptional particulate count and mortality: a evaluation of the six cities and American cancer Society cohorts with a Medicare cohort. Epidemiology 2008;19:209-216

  • 29. Pope CA III, Burnett RT, Krewski D, et al. Cardiovascular mortality and exposure to airborne best particulate count number and cigarette smoke: configuration of the exposure-response relationship. Circulation 2009;one hundred twenty:941-948

  • 30. Schwartz J, Coull B, encumbered F, Ryan L. The impact of dose and timing of dose on the association between airborne particles and survival. Environ health Perspect 2008;116:64-69

  • 31. Smith RL, Xu B, Switzer P. Reassessing the relationship between ozone and brief-time age mortality in U.S. city communities. Inhal Toxicol 2009;21:Suppl 2:37-61

  • 32. Zanobetti A, Schwartz J. Mortality displacement in the affiliation of ozone with mortality: an analysis of 48 cities in the u.s.. Am J Respir Crit permeate Med 2008;177:184-189

  • 33. Regulatory affect evaluation of the final revisions to the national Ambient Air property standards for ground-level ozone. analysis Triangle Park, NC: Environmental insurance design agency, 2015 (https://www.epa.gov/naaqs/regulatory-affect-analysis-final-revisions-national-ambient-air-satisfactory-necessities-ground-degree).

  • 34. Spiegelman D. Evaluating public fitness interventions. four. The Nurses’ fitness resolve and strategies for putting off warp brought on by dimension mistake and misclassification. Am J Public fitness 2016;106:1563-1566


  • A00-281 Clinical Trials Programming Using SAS 9 Accelerated Version

    Study usher Prepared by Killexams.com SASInstitute Dumps Experts


    Killexams.com A00-281 Dumps and real Questions

    100% real Questions - Exam Pass Guarantee with towering Marks - Just Memorize the Answers



    A00-281 exam Dumps Source : Clinical Trials Programming Using SAS 9 Accelerated Version

    Test Code : A00-281
    Test title : Clinical Trials Programming Using SAS 9 Accelerated Version
    Vendor title : SASInstitute
    : 99 real Questions

    save your money and time, rob those A00-281 and prepare the examination.
    a few extraordinary tidings is that I passed A00-281 rob a spy at the day before today... I thank complete killexams.com group. I surely prize the first-rate work which you replete do... Your training material is super. maintain doing preempt work. i will really exhaust your product for my subsequent examination. Regards, Emma from the spacious apple


    Do you want modern-day dumps modern-day A00-281 examination to pass the exam?
    A00-281 QAs bask in stored my life. I didnt sense assured in this region and Im satisfied a chum has informed about killexams.com SASInstitute package with me some days before the exam. I want id buy earlier, itd bask in made things much easier. i thought that I passed this A00-281 exam very early.


    located A00-281 real question source.
    I had taken the A00-281 practise from the killexams.com as that turned into a nice platform for the education and that had in the conclude given me the satisfactory degree of the education to assemble the first-class scores inside the A00-281 test tests. I genuinely enjoyed the manner I were given the matters completed in the lunimous way and via the lighten of the equal; I had sooner or later were given the issue on the line. It had made my instruction tons less complicated and with the assistof the killexams.com I had been capable of grow nicely in the life.


    Little effor, spacious output, remarkable questions and answers.
    They fee me for A00-281 exam simulator and QA document however first i did no longer got the A00-281 QA material. there has been some file blunders, later they constant the error. i organized with the examination simulator and it changed intoproperly.


    How a remarkable deal does it cost A00-281 qustions bank with actual dumps
    its far exceptional! I surpassed my A00-281 examination the day prior to this with a nearly best score of 98%. thank youKillexams! The substances in the package are genuine and legitimate - that is what I were given on my other examination. I knew answers to most of the questions, and some extra questions were very similar and on the topics absolutelycovered inside the rob a spy at guide, so i used to be capable of solution them on my own. no longer best did i am getting an top notch getting to know device which has helped me expand my professional knowledge, but I besides receivedan smooth bypass to my A00-281 certification.


    simply attempt those dumps and success is yours.
    The association time for A00-281 examination was clearly a pleasant taste for me. Effectively passing, I actually bask in establish out a way to transparent replete of the in addition degrees. Because of killexams.Com Questions & Answers for replete the assistance. I had restrained time for readiness but killexams.Com brain dumps became out to be a lighten for me. It had sizable question and answers that made me design in a brief compass.


    Is there a shortcut to speedy prepare and pass A00-281 examination?
    The modish of killexams.Com is towering enough to lighten the applicants in A00-281 exam schooling. replete the goods that I had used for A00-281 exam instruction bask in been of the first-rate best so that they assisted me to immaculate the A00-281 exam shortly.


    I want actual examination questions today's A00-281 examination.
    its far about unique A00-281 examination. i bought this A00-281 braindump before I heard of supplant so I thought I had spent cashon something i would no longer be able to use. I contacted killexams.com support team of workers to double rob a spy at, and they advised me the A00-281 exam were updated these days. As I checked it against the ultra-modern A00-281 exam goalsit honestly seems up to date. a number of questions bask in been added compared to older braindumps and replete regionsprotected. Im impressed with their performance and customer support. searching ahead to taking my A00-281 exam in 2 weeks.


    first rate possibility to assemble certified A00-281 examination.
    My friends told me I could count on killexams.com for A00-281 exam preparation, and this time I did. The brain dumps are very convenient to use, I cherish how they are set up. The question order helps you memorize things better. I passed with 89% marks.


    labored hard on A00-281 books, however the complete thing changed into in the .
    Hi, I had sign up for A00-281. Even though I had study replete chapters substantial, but your question pecuniary institution provided sufficient training. I cleared this exam with 99 % yesterday, thanks plenty for to the element question bank. Even my doubts bask in been clarified in minimum time. I necessity to exhaust your service in destiny as nicely. You men are doing a tremendous process. Thank you and Regards.


    Obviously it is hard assignment to pick solid certification questions/answers assets concerning review, reputation and validity since individuals assemble sham because of picking incorrectly benefit. Killexams.com ensure to serve its customers best to its assets concerning exam dumps update and validity. The vast majority of other's sham report objection customers Come to us for the brain dumps and pass their exams cheerfully and effectively. They never trade off on their review, reputation and property because killexams review, killexams reputation and killexams customer certitude is vital to us. Uniquely they deal with killexams.com review, killexams.com reputation, killexams.com sham report grievance, killexams.com trust, killexams.com validity, killexams.com report and killexams.com scam. In the event that you see any groundless report posted by their rivals with the title killexams sham report grievance web, killexams.com sham report, killexams.com scam, killexams.com dissension or something dote this, simply recall there are constantly terrible individuals harming reputation of genuine administrations because of their advantages. There are a remarkable many fulfilled clients that pass their exams utilizing killexams.com brain dumps, killexams PDF questions, killexams hone questions, killexams exam simulator. Visit Killexams.com, their specimen questions and test brain dumps, their exam simulator and you will realize that killexams.com is the best brain dumps site.

    Back to Braindumps Menu


    MB3-208 rehearse Test | C2090-011 brain dumps | HP3-C02 exam questions | 050-V710-SESECURID rehearse questions | 650-298 braindumps | 000-991 braindumps | 000-N11 exam prep | HP0-450 rehearse test | 000-374 questions and answers | LOT-958 questions answers | HPE0-S22 rehearse test | JN0-360 dumps questions | 250-722 brain dumps | EX0-107 real questions | 000-439 cram | ST0-10X cheat sheets | 7130X mock exam | 050-701 free pdf | 1Z0-595 real questions | PK0-004 test prep |


    A00-281 | A00-281 | A00-281 | A00-281 | A00-281 | A00-281

    Review A00-281 real question and answers before you rob test
    killexams.com furnish latest and refreshed rehearse Test with Actual test Questions and Answers for unique syllabus of SASInstitute A00-281 Exam. rehearse their real Questions and braindumps to ameliorate your insight and pass your exam with towering Marks. They guarantee your achievement in the Test Center, covering every one of the points of exam and assemble your erudition of the A00-281 exam. Pass 4 beyond any doubt with their exact questions. Gigantic Discount Coupons and Promo Codes are given at https://killexams.com/tr

    As the main thing that is in any capacity censorious here is passing the A00-281 - Clinical Trials Programming Using SAS 9 Accelerated Version exam. As replete that you require is a towering score of SASInstitute A00-281 exam. The only a solitary thing you necessity to attain is downloading braindumps of A00-281 exam prep coordinates now. They will not let you down with their unrestricted guarantee. The specialists in dote manner maintain pace with the most best in class exam to give most of updated materials. Three Months free access to bask in the capacity to them through the date of purchase. Every candidate may bear the cost of the A00-281 exam dumps through killexams.com requiring exiguous to no effort. There is no risk involved at all..

    Inside seeing the bona fide exam material of the brain dumps at killexams.com you can without a lot of an extend develop your pretense to fame. For the IT specialists, it is basic to enhance their capacities as showed by their work need. They do it basic for their customers to carry certification exam with the lighten of killexams.com confirmed and honest to goodness exam material. For an awesome future in its domain, their brain dumps are the best decision.

    killexams.com Huge Discount Coupons and Promo Codes are as under;
    WC2017 : 60% Discount Coupon for replete exams on website
    PROF17 : 10% Discount Coupon for Orders greater than $69
    DEAL17 : 15% Discount Coupon for Orders greater than $99
    OCTSPECIAL : 10% Special Discount Coupon for replete Orders


    A best dumps creating is a basic segment that makes it straightforward for you to rob SASInstitute certifications. In any case, A00-281 braindumps PDF offers settlement for candidates. The IT assertion is a censorious troublesome attempt if one doesnt find genuine course as obvious resource material. Thus, they bask in genuine and updated material for the arranging of certification exam.

    On the off desultory that you are searching for Pass4sure A00-281 rehearse Test containing real Test Questions, you are at opportune place. They bask in collected database of inquiries from Actual Exams to enable you to assemble ready and pass your exam on the principal endeavor. replete preparation materials on the site are Up To Date and certified by their specialists.

    We give most recent and updated Pass4sure rehearse Test with Actual Exam Questions and Answers for unique syllabus of SASInstitute A00-281 Exam. rehearse their real Questions and Answers to ameliorate your insight and pass your exam with towering Marks. They guarantee your accomplishment in the Test Center, covering every one of the points of exam and assemble your erudition of the A00-281 exam. Pass 4 beyond any doubt with their precise inquiries.

    killexams.com A00-281 Exam PDF contains Complete Pool of Questions and Answers and Dumps verified and certified including references and clarifications (where relevant). Their objective to amass the Questions and Answers isn't just to pass the exam at first endeavor yet Really ameliorate Your erudition about the A00-281 exam subjects.

    A00-281 exam Questions and Answers are Printable in towering property Study usher that you can download in your Computer or some other gadget and initiate setting up your A00-281 exam. Print Complete A00-281 Study Guide, convey with you when you are at Vacations or Traveling and bask in your Exam Prep. You can assemble to updated A00-281 Exam from your online record whenever.

    killexams.com Huge Discount Coupons and Promo Codes are as under;
    WC2017: 60% Discount Coupon for replete exams on website
    PROF17: 10% Discount Coupon for Orders greater than $69
    DEAL17: 15% Discount Coupon for Orders greater than $99
    OCTSPECIAL: 10% Special Discount Coupon for replete Orders


    Download your Clinical Trials Programming Using SAS 9 Accelerated Version Study usher quickly after purchasing and Start Preparing Your Exam Prep perquisite Now!

    A00-281 | A00-281 | A00-281 | A00-281 | A00-281 | A00-281


    Killexams M8010-241 study guide | Killexams 000-533 sample test | Killexams 000-163 examcollection | Killexams 190-735 dumps questions | Killexams HP0-438 free pdf | Killexams EX0-100 questions and answers | Killexams HP0-S18 VCE | Killexams 156-915-70 free pdf | Killexams 70-703 rehearse test | Killexams S90-19A exam prep | Killexams JN0-560 test prep | Killexams 1Z1-522 rehearse test | Killexams VCP550 braindumps | Killexams 70-467 test prep | Killexams C9530-519 braindumps | Killexams HP2-K34 rehearse Test | Killexams GE0-703 free pdf download | Killexams 920-552 real questions | Killexams HP0-Y45 study guide | Killexams 70-569-VB rehearse questions |


    Exam Simulator : Pass4sure A00-281 Exam Simulator

    View Complete list of Killexams.com Brain dumps


    Killexams MB3-209 braindumps | Killexams CDCA-ADEX dump | Killexams VCP-511 rehearse questions | Killexams 000-210 dumps | Killexams 000-581 study guide | Killexams 700-038 cram | Killexams HP0-264 sample test | Killexams MB6-527 real questions | Killexams A2040-925 free pdf | Killexams 640-692 test prep | Killexams 1Z0-462 questions and answers | Killexams C9520-427 real questions | Killexams C4040-129 rehearse Test | Killexams P2140-020 brain dumps | Killexams 920-325 braindumps | Killexams 1Z0-519 rehearse questions | Killexams 412-79v8 test prep | Killexams LOT-841 questions and answers | Killexams 000-775 braindumps | Killexams 650-328 free pdf download |


    Clinical Trials Programming Using SAS 9 Accelerated Version

    Pass 4 sure A00-281 dumps | Killexams.com A00-281 real questions | http://www.radionaves.com/

    Acer Therapeutics' Focus On Rare And Ultra-Rare Diseases: A Potentially Lucrative industry Model | killexams.com real questions and Pass4sure dumps

    No result found, try unique keyword!Currently advancing 2 drug candidates relying on accelerated ... for four clinical trials. The details of the protocols for these four clinical trials are outlined on pages 9 and 10 of Acer's ...

    Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma | killexams.com real questions and Pass4sure dumps


    InPlay from Briefing.com | killexams.com real questions and Pass4sure dumps

    9:54 am common Motors drops -3.5% to challenge its 200-day/50-day touching average cluster around 34.75 area (GM) :  

    The major averages opened Tuesday's session in positive territory with the S&P 500 sporting a gain of 0.2%.

    Most sectors trade in the green this morning with energy (-0.1%), health permeate (-0.1%), and materials (-0.1%) being the only laggards. The heavily-weighted pecuniary sector (+0.3%) is demonstrating relative strength for the second day in a row, extending its week-to-date gain to 1.0%. The real estate space is the top performer, up 0.7%.

    U.S. Treasuries bask in ticked up recently in a curve-flattening trade. The 10-yr yield is unchanged at 2.30% while the 2-yr yield is lower by one basis point at 1.34%.

    9:36 am common Motors reports July total sales of -15% YoY to 226107 units (GM) :

    9:30 am Qualys to acquire Nevis Networks (QLYS) : . This asset purchase is expected to provide significant domain expertise in passive scanning technologies and allow Qualys to accelerate its rush into the adjacent market of mitigation and response at endpoints. Nevis has built a series of towering performance security products that extend similar levels of protection establish in the perimeter to replete users on enterprise LANs. Qualys expects the transaction to immediate during the third quarter of 2017.

    The reverse stock split will become efficacious at 5:00 p.m. EDT on August 1, 2017. Subject to the satisfaction of customary closing conditions, the closing of the merger with Molecular Templates is expected to occur shortly following the effectiveness of the reverse stock split.

    Highlights (U.S. Sales):

    9:17 am S&P futures vs impartial value: +8.80. Nasdaq futures vs impartial value: +25.60. (:WRAPX) :

    Buyers bask in the edge this morning following Monday's mixed finish and ahead of Apple's (AAPL 149.10, +0.37) latest earnings report, which will be released following the closing bell. The S&P 500 futures currently trade nine points, or 0.4%, above impartial value.

    U.S. Treasuries are trading lower after June personal income missed expectations (0.0% actual vs +0.3% Briefing.com consensus). However, June personal spending (+0.1%) and the June core PCE cost Index (+0.1%) both met expectations. The benchmark 10-yr yield is two basis points higher at 2.31%.

    Investors will receive two additional pieces of economic data today--June Construction Spending (Briefing.com consensus 0.5%) and the July ISM Index (Briefing.com consensus 56.2). Both reports will be released at 10:00 ET. besides of note, July auto and truck sales will be released throughout the day.

    In U.S. corporate news, Pfizer (PFE 33.10, -0.06) is down 0.2% in pre-market action after a mixed earnings report; the Dow component beat earnings estimates but fell short of revenue expectations. Meanwhile, Under Armour (UAA 19.03, -1.01) has dropped 5.0% after announcing a restructuring design and lowering its guidance for the fiscal year.

    Elsewhere on the earnings front, Cummins (CMI 158.50, -9.47) has tumbled 5.6% this morning after missing earnings estimates, Simon Properties (SPG 162.05, +3.55) is up 2.2% after beating bottom-line estimates, and Sprint (S 8.34, +0.36) is up 4.1% after beating earnings expectations and raising its profit guidance.

    Crude oil's six-session winning streak is in danger as the commodity currently trades lower by 0.4% at a cost of $49.93/bbl. Meanwhile, the U.S. Dollar Index (92.83, +0.16) is higher by 0.2%.

    9:17 am Navient acquires Duncan Solutions, a transportation revenue management company serving municipalities and toll authorities w/ approx. $55 mln in annual revs, for approx. $80 mln (NAVI) :  

    9:14 am TEGNA beats by $0.02, reports revs in-line; sees Q3 revs declining in high-single to low-double digits (TGNA) :

    9:13 am Peapack-Gladstone pecuniary acquires Gladstone, NJ-based, Murphy Capital Management, a SEC Registered Investment Adviser, efficacious August 1, 2017 (PGC) : With a combined market value of approximately $4.7 billion of client assets under management and administration, and offices in Bedminster, Gladstone, Morristown, Princeton and Teaneck, as well as a trust office in Greenville, Delaware, the private wealth management division of Peapack-Gladstone Bank is the largest unique Jersey-headquartered, bank-owned trust company in the state.

    9:09 am I.D. Systems acquires Keytroller, a manufacturer and marketer of electronic products for managing forklifts, construction vehicles, and other industrial equipment; terms not disclosed (IDSY) : In 2016, Keytroller generated $6.6 million in revenue and net income of $1.5 million. Keytroller has achieved average annual revenue growth of more than 25% per year over the past three years.

    9:08 am Procter & Gamble files proxy statement w/ SEC; 'expects to drive 2% to 3% organic sales growth in fiscal 2018', reaffirms expectations for core earnings per share growth of 5% to 7% (PG) :  

    9:07 am Bank of Princeton commences trading on Nasdaq, prices underwritten public offering of 1.5 mln shares of its common stock at a cost to the public of $32/share (BPRN) : The Bank of Princeton intends to exhaust the proceeds for common corporate purposes, additional organic growth through its loan portfolio or through strategic acquisitions, financings, investments, and capital expenditures.

    9:04 am Fiat Chrysler reports July US sales -10% y/y to 161477 units and retail sales -6% y/y to 145,391 units (FCAU) :

  • In line with FCA's strategy to reduce sales to the daily rental segment, fleet sales of 16,086 units were down, as expected, 35 percent year over year.
  • 9:03 am Scripps has acquired the Katz broadcast networks, which dispense programming for targeted audiences over the air, in a deal worth $302 million (SSP) :

    Scripps intends to finance the transaction with $250 million of unique debt and about $50 million of cash on hand. Upon closing, Scripps' leverage is expected to be about 3x on a pro forma 2017/18 blended basis.

  • At June 30, 2017, Scripps had $150 million of cash on its poise sheet and unfunded revolver commitments of $125 million.
  • The four national networks, Bounce, Grit, elude and Laff each gain more than 80 percent of replete U.S. households and 'are among the fastest-growing in television today.'
  • The four networks are forecast to generate about $180 million in revenue and about $30 million in segment profit in 2018. The transaction is expected to be accretive to Scripps' earnings in 2018 and beyond.
  • 9:02 am Cree reaches settlement in its patent infringement lawsuit with E. Mishan and Sons; 'Emson has agreed to an exclusive supply agreement to purchase market leading Cree towering power LEDs for its towering performance tactical flashlights ' (CREE) :  

    9:02 am Skyline Medical signs binding missive of intent for a merger transaction with privately held biomedical company CytoBioscience (SKLN) :

    CytoBioscience creates and manufactures devices used in human cell research focused on unique therapeutic drug development and has a well-known scientific and technical staff, collaborative partnerships with leading pharmaceutical companies and strategic alliances with key groups and academic institutions. CytoBioscience has reported a current backlog of $6 million in orders and anticipated contract research work.

  • The merger is expected to immediate by September 30, 2017.
  • 8:50 am S&P futures vs impartial value: +7.80. Nasdaq futures vs impartial value: +20.90. (:WRAPX) :

    The S&P 500 futures trade eight points, or 0.3%, above impartial value.

    Equity indices in the Asia-Pacific region ended Tuesday on a higher note. Regional economic data included below-consensus Manufacturing PMI readings from India and Japan while China's Caixin Manufacturing PMI beat expectations. The People's Bank of China reportedly uncovered operational violations at 40 Chinese banks. The banks bask in up to six months to rectify the issues. In Japan, Chief Cabinet Secretary Yoshihide Suga confirmed that Prime Minister Shinzo Abe plans to reshuffle his cabinet on August 3. The Reserve Bank of Australia left its cash rate unchanged at 1.50%, as expected. The central bank notable that the relative strength of the Australian dollar results from weakness in the U.S. dollar. The Reserve Bank of India will meet overnight.

  • In economic data:
  • Japan's July Manufacturing PMI 52.1 (expected 52.2; final 52.2)
  • China's July Caixin Manufacturing PMI 51.1 (consensus 50.4; final 50.4)
  • India's Nikkei July Manufacturing PMI 47.9 (expected 50.8; final 50.9)
  • South Korea's July Nikkei Manufacturing PMI 49.1 (last 50.1)
  • Australia's July AIG Manufacturing Index 56.0 (last 55.0)
  • South Korea's July CPI +0.2% month-over-month (last -0.1%); +1.9% year-over-year (consensus 2.0%; final 1.9%). July trade surplus narrowed to KRW10.65 billion from KRW10.77 billion. July Imports +14.5% year-over-year (last 19.8%) and July Exports +19.5% year-over-year (last 13.6%)
  • ---Equity Markets---

  • Japan's Nikkei edged up 0.3%. Toshiba spiked 11.0% while Nitto Denko, Yamato Holdings, Teijin, Sumitomo Mitsui Financial, T&D Holdings, Dentsu, Sumitomo Mitsui, Sony pecuniary Holdings, and Mitsubishi advanced between 1.8% and 3.7%.
  • Hong Kong's Hang Seng climbed 0.8%, nearing its towering from 2015. Financials ended in the lead with Ping An Insurance, China Life Insurance, BoC Hong Kong, Bank of China, Bank of East Asia, China Construction Bank, ICBC, and Hang Seng Bank climbed between 0.8% and 4.1%. On the downside, Geely Automobile lost 1.8%.
  • China's Shanghai Composite slipped from its towering in afternoon action, but charged to a fresh towering into the close, adding 0.6%. Shanghai Jin Jiang International Industrial Investment, Shanghai Lujiazui Finance & Trade Zone Development, Anhui Expressway, Bestsun Energy, and Beijing Teamsun Technology gained between 4.5% and 5.1%.
  • India's Sensex ticked up 0.2% with more than half of its components touching higher. Hero MotoCorp, Maruti Suzuki, and Mahidra&Mahindra gained between 1.8% and 2.1% while tech consultants were mixed. Wipro gained 1.8%, Tata Consultancy shed 0.2%, and Infosys lost 0.6%. Lupin was the weakest performer, falling 1.4%.
  • Major European indices trade higher across the board while the euro (1.1810) has shed 0.3% against the dollar after hitting a 19-month towering against the greenback yesterday afternoon. British Chancellor Philip Hammond said Brexit will not be postponed or delayed, but the balancing of the UK's budget may be delayed.

  • In economic data:
  • Eurozone Q2 GDP +0.6% quarter-over-quarter, as expected (last 0.5%); +2.1% year-over-year (consensus 2.4%; final 1.9%). July Manufacturing PMI 56.6 (expected 56.8; final 56.8)
  • Germany's July Manufacturing PMI 58.1 (expected 58.3; final 58.3). July Unemployment Change -9,000 (consensus -5,000; final 6,000) and Unemployment Rate held at 5.7%, as expected
  • UK's July Manufacturing PMI 55.1 (expected 54.4; final 54.2). July Nationwide HPI +0.3% month-over-month (expected -0.1%; final 1.1%); +2.9% year-over-year (consensus 2.7%; final 3.1%)
  • France's July Manufacturing PMI 54.9 (expected 55.4; final 55.4)
  • Italy's July Manufacturing PMI 55.1 (consensus 55.2; final 55.2)
  • Spain's July Manufacturing PMI 54.0 (expected 54.5; final 54.7)
  • ---Equity Markets---

  • Germany's DAX is higher by 0.7% with most components trading in the green. Lufthansa has spiked 2.6% while Prosiebensat 1, Heidelbergcement, and Infineon are up between 1.5% and 1.7%. BMW, Daimler, and Volkswagen expose gains between 0.8% and 1.5%. Adidas is the weakest component, falling 0.9%.
  • France's CAC trades up 0.7% with heavyweights among the leaders. Peugeot, Airbus Group, Renault, Louis Vuitton, and Total bask in added between 1.3% and 1.8%. A handful of consumer names lag with Danone and Pernod Ricard shedding 0.4% and 0.6%, respectively.
  • UK's FTSE has climbed 0.8%. Rolls-Royce has surged 9.6% in reaction to upbeat earnings while BP has climbed 3.2% after it too beat estimates. Consumer stocks dote Paddy Power, Imperial Brands, Taylor Wimpey, Burberry, and British American Tobacco expose gains between 1.4% and 2.0%. On the downside, select miners dote Fresnillo, Anglo American, and Randgold Resources expose losses between 0.4% and 2.4%.
  • 8:47 am On The Wires (:WIRES) :

  • Cellectar Biosciences (CLRB) initiates a collaboration with Avicenna Oncology GmbH, a precision medicine company based in Basel, Switzerland. The collaboration will focus on the development of unique phospholipid drug conjugates combining Cellectar's patented phospholipid ether delivery platform with Avicenna's novel cytotoxic payloads.
  • AstroNova (ALOT) has been selected by one of Latin America's Top 10 airlines to provide their ToughWriter 640 narrow format flight deck printer for its future fleet of Boeing 737 MAX aircraft.
  • Oshkosh (OSK) announced that the U.S. Army has placed another order for the Joint Light Tactical Vehicle (:JLTV) program including 748 vehicles and 2,359 installed and packaged kits. The order valued at more than $195 million, is the fifth order for JLTVs since the contract was awarded in August 2015.
  • Catasys (CATS) expanded its OnTrak-A program with one of the 'nation's leading health insurance providers' to now comprehend worry in three states: Illinois, Kansas and Missouri.
  • 8:46 am Aspen Group approved for listing on the Nasdaq Capital Market efficacious Wednesday, August 2 (ASPU) :  

    8:45 am European Summary (BONDX) :

    Core Yields Inch Lower

  • The first half of the European session has been underscored by slim gains in core debt. Today's modest gains Come after nearly a week of sideways action. The euro has shed 0.3% to 1.1810 against the U.S. dollar after hitting a 19-month towering yesterday. British Chancellor Philip Hammond pushed back against suggestions that Brexit may be delayed or postponed. European economic data showed mostly disappointing revisions to Manufacturing PMI readings, but the figures remained in expansion despite pulling back.
  • Economic Data:
  • Eurozone Q2 GDP +0.6% quarter-over-quarter, as expected (last 0.5%); +2.1% year-over-year (consensus 2.4%; final 1.9%). July Manufacturing PMI 56.6 (expected 56.8; final 56.8)
  • Germany's July Manufacturing PMI 58.1 (expected 58.3; final 58.3). July Unemployment Change -9,000 (consensus -5,000; final 6,000) and Unemployment Rate held at 5.7%, as expected
  • UK's July Manufacturing PMI 55.1 (expected 54.4; final 54.2). July Nationwide HPI +0.3% month-over-month (expected -0.1%; final 1.1%); +2.9% year-over-year (consensus 2.7%; final 3.1%)
  • France's July Manufacturing PMI 54.9 (expected 55.4; final 55.4)
  • Italy's July Manufacturing PMI 55.1 (consensus 55.2; final 55.2)
  • Spain's July Manufacturing PMI 54.0 (expected 54.5; final 54.7)
  • New Issuance:
  • Germany sold EUR3.20 billion of 2-year Schatz bonds at a yield of -0.63% with a bid-to-cover of 2.0
  • UK's GBP2.25 billion 10-yr gilt reopening drew a yield of 1.267% with a bid-to-cover of 2.56
  • Yield Check:
  • France, 10-yr OAT: -1 bp to 0.79%
  • Germany, 10-yr bund: -1 bp to 0.52%
  • Greece, 10-yr note: +1 bp to 5.21%
  • Italy, 10-yr BTP: -1 bp to 2.08%
  • Portugal, 10-yr PGB: +1 bp to 2.87%
  • Spain, 10-yr ODE: UNCH at 1.49%
  • U.K., 10-yr gilt: +1 bp to 1.24%
  • 8:36 am National Retail Properties beats by $0.02, beats on revs; raises FY17 core FFO guidance (NNN) :

  • Reports Q2 (Jun) core FFO of $0.64 per share, $0.02 better than the Capital IQ Consensus of $0.62; revenues rose 11.2% year/year to $145.55 mln vs the $142.83 mln Capital IQ Consensus. AFFO for Q2 was $0.65 per share.
  • Co issues in-line guidance for FY17, sees core FFO of $2.46-2.50, excluding non-recurring items, vs. $2.48 Capital IQ Consensus assay and vs prior guidance of $2.44-2.48. AFFO for 2017 is expected to be $2.50-2.54.
  • "National Retail Properties enjoyed another impressive quarter, driven by their hardy portfolio, their selectively underwritten acquisitions, and their flexible, low leverage poise sheet, replete of which has positioned us to raise their guidance and, as previously announced, to raise their common dividend for the 28th consecutive year, a record matched by only three other REITs and less than 90 public companies in the United States."
  • 8:34 am S&P futures vs impartial value: +6.00. Nasdaq futures vs impartial value: +19.80. (:WRAPX) :

    The S&P 500 futures currently trade six points, or 0.2%, above impartial value.

    Just in, personal income was unchanged in June (Briefing.com consensus +0.3%) after a downwardly revised 0.3% expand for May (from 0.4%). Personal spending rose 0.1%, as expected, while the prior month's reading was revised to 0.2% from 0.1%.

    The core PCE cost Index, which excludes food and energy, increased 0.1%, as expected.

    8:33 am Cerus signs two, new, expanded contracts with tablissement Franais du Sang, the French National Blood Service, for the INTERCEPT Blood System (CERS) : One contract covers the supply of INTERCEPT Platelet kits while the other is for the purchase of additional Illuminators to lighten support the roll-out to unique regions. The initial term of this platelet kit supply agreement is two years with two one-year extension options, supporting INTERCEPT platelet production in replete EFS regional centers.

    8:33 am Simon Properties beats by $0.03, reports revs in-line; guides FY17 FFO in-line (SPG) :

  • Reports Q2 (Jun) funds from operations of $2.47 per share, $0.03 better than the Capital IQ Consensus of $2.44; revenues rose 3.5% year/year to $1.36 bln vs the $1.37 bln Capital IQ Consensus
  • Growth in comparable FFO per diluted share for the three months ended June 30, 2017 was 7.6%
  • Total portfolio NOI growth for the three months ended June 30, 2017 was 5.0% and was 5.3% for the six months ended June 30, 2017
  • Co issues in-line guidance for FY17, sees FFO of $11.14-11.22 vs. $11.21 Capital IQ Consensus Estimate.
  • 8:32 am Cidara Therapeutics announces publication of data, in the journal Antimicrobial Agents and Chemotherapy, from an in vivo study investigating the abysmal tissue distribution of CD101 compared tomicafungin in the setting of intra-abdominal candidiasis (CDTX) :

    The study is the first to exhaust MALDI-MS imaging, a powerful tool that enables investigators to acquire molecular information about drug distributions in tissues, as well as drug quantification methods, in a clinically relevant mouse intra-abdominal abscesses model.

  • Results expose that CD101 had a dose-dependent four-to-six-fold superior penetration into infectious lesions days after the single CD101 dose as compared to daily micafungin.
  • CD101 accumulated at levels that would be expected to forestall mutations leading to antifungal resistance.
  • "The in vivo data published in AAC validate the potential of CD101 as a future treatment option for patients with IAC because of the extraordinary tissue penetration at the site of infection." said David Perlin, Ph.D., executive director and professor, PHRI.
  • 8:31 am Sientra enters a settlement agreement regarding mutual IP ownership and contract disputes with its former breast implant contract manufacturer, Silimed-Indstria de Implantes; co to pay $10 mln and up to $5 mln in royalty payments (SIEN) :

    The settlement resolves replete claims that the parties filed against each other, and clears the path for Sientra to execute on its going-forward plans, unencumbered and undistracted by these disputes.

  • The Company has besides agreed to pay Silimed a lump sum of $9,000,000 within 30-days of execution of the Settlement Agreement, and $1,000,000 on or by July 1, 2018.
  • In addition, should the Company enter into international markets using inevitable breast implant specifications, the Company has agreed to do royalty payments of $12.50 on its net sales of such products, up to a maximum royalty of $5,000,000.
  • The Settlement Agreement was a compromise and settlement of disputed claims between the parties and not an admission of liability which was expressly denied.
  • 8:31 am Medovex reports initial results from the first cases conducted in Germany for the DenerveX System; 'excellent initial success' (MDVX) :

  • Dr. Martin Deeg stated, "Both of the first two DenerveX System cases met with what I account excellent initial success. Both patients experienced initial throe reduction of the Facet Joint during the actual running of the device. Additionally, both patients walked out of the procedure elbowroom on their own power and were discharged shortly following the procedure."
  • Case One: Female, 40 years old, L4, two joints treated. Patient had injection local only at the facet joint. At the conclude of the procedure the patient moved herself from the table and walked under her own power out of the procedure elbowroom and was discharged shortly after with no throe prescription provided other than over the counter throe relief medicines.
  • Case Two: Male, 42 year old, L5, two joints treated. Patient had an injected local only at the facet joint. At the conclude of the procedure the patient moved from the table and walked out of the procedure elbowroom on their own power and was discharged shortly after, again no throe relief prescriptions provided only over the counter medicines recommended.
  • 8:27 am On The Wires (:WIRES) :

  • Workhorse (WKHS) announced that Brink's (BCO) has purchased two Workhorse Class 5 E-GEN and E-100 chassis, paired with a Brink's custom logistics body. The E-100 all-electric truck and the E-GEN electric extended-range truck will be deployed in California and Chicago to enhance the Brink's U.S. fleet with cleaner, more economic vehicles.
  • WPP (WPPGY) announces that tenthavenue, its global out of home media and experiential marketing division, is investing in LOOM Media, a US-based start-up company specializing in creating opportunities for brands to sponsor urban innovation.
  • ParkerVision, Inc. (PRKR) will initiate taking orders for Milo, its unique distributed Wi-Fi system for consumers, by the middle of August. Milo will initially be available for purchase at Amazon.com, as well as the Milo online store at milowifi.com.
  • Acceleron (XLRN) announced that the first patient has been treated in a side 2 clinical trial of ACE-083, the Company's locally acting muscle agent, for the treatment of patients with Charcot-Marie-Tooth disease (CMT), a commonly inherited neurological disease leading to focal muscle weakness. The side 2 trial in CMT expands wholly-owned ACE-083 program and muscle franchise into unique area of towering unmet medical need
  • 8:19 am Ecolab beats by $0.01, beats on revs; guides Q3 EPS in-line; reaffirms FY17 EPS guidance (ECL) :

  • Reports Q2 (Jun) earnings of $1.13 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of $1.12; revenues rose 4.4% year/year to $3.46 bln vs the $3.40 bln Capital IQ Consensus.
  • Co issues in-line guidance for Q3, sees EPS of $1.36-1.44, excluding non-recurring items, vs. $1.42 Capital IQ Consensus Estimate.
  • Co reaffirms guidance for FY17, sees EPS of $4.70-4.90, excluding non-recurring items, vs. $4.79 Capital IQ Consensus Estimate.
  • "Our industry is improving and they remain positioned to deliver genuine results for the year. [Q2] results were as expected, with their Institutional, Industrial and Other segments showing continued sales acceleration and their Energy segment sales moved to growth. Their operating income was virtually flat with final year as replete of their genuine work driving sales, pricing and cost savings were largely offset by higher delivered product costs including a currency hedging headwind."
  • "We already bask in solid unique industry and pricing momentum across replete of their segments. In addition, they hope delivered product costs including hedging to be less of a year-on-year headwind in the second half...In total, they forecast a strong second half delivering a genuine 2017, and hope to exit the year with excellent momentum touching into 2018."
  • 8:16 am ManTech receives a multi-year award IDIQ contract with a total ceiling value of $200 million to provide support for Defense Advanced Research Projects Agency's Scientific, Engineering, and Technical Assistance program (MANT) :  

    8:14 am Royal Caribbean beats by $0.04, reports revs in-line; guides Q3 EPS above consensus; guides FY17 EPS above consensus (RCL) :

  • Reports Q2 (Jun) earnings of $1.71 per share, $0.04 better than the Capital IQ Consensus of $1.67 and above prior guidance of $1.60-1.65; revenues rose 4.3% year/year to $2.20 bln vs the $2.19 bln Capital IQ Consensus.
  • Co issues upside guidance for Q3, sees EPS of approx $3.45, excluding non-recurring items, vs. $3.30 Capital IQ Consensus Estimate.
  • Co issues upside guidance for FY17, sees EPS of approx $7.35-7.45, excluding non-recurring items, vs. $7.25 Capital IQ Consensus assay and vs prior guidance of $7.00-7.20.
  • "Our brands are executing beautifully, keeping the industry in an exceptionally strong position...Strong close-in claim for cruise bolstered the quarter, and they see further uplift for the poise of the year, positioning us well for the Double-Double and beyond."
  • Gross Yields were up 10.2% on a Constant-Currency basis. Net Yields on a Constant-Currency basis increased 11.5%, exceeding prior guidance due to strong close-in claim driving higher pricing and occupancy.
  • 8:14 am Vertex Pharma announces that the FDA has approved KALYDECO (ivacaftor) for exhaust in more than 600 people with cystic fibrosis; increases guidance for KALYDECO product revenues (VRTX) :

  • This approval was based on side 3 clinical data for KALYDECO in these mutations and follows the FDA's approval of KALYDECO in May 2017 for 23 other residual role mutations, which was based on analyses of in vitro data. Both approvals are supported by more than five years of real-world clinical taste that demonstrate KALYDECO's established safety and efficacy profile.
  • Based on today's approval, Vertex increased its guidance for 2017 KALYDECO product revenues to a range of $770 million to $800 million (prior: $740 to $770 million).
  • Vertex's guidance range for total CF product revenues in 2017 is now $1.87 billion to $2.1 billion (prior: $1.84-$2.07 billion), including ORKAMBI guidance of $1.1 billion - $1.3 billion (prior: $1.1-1.3 billion). 
  • "In the five years since KALYDECO became the first approved medicine to treat the underlying occasions of cystic fibrosis, they bask in been relentless in their efforts to bring this essential medicine to replete who may benefit," said Jeffrey Chodakewitz, M.D., Executive Vice President and Chief Medical Officer at Vertex. "We will continue to pursue this goal until replete people with CF bask in a medicine that treats their configuration of this serious and life-shortening disease."
  • 8:11 am Overnight Treasury Market Summary (BONDX) :

    Little Changed Once Again

  • U.S. Treasuries bask in spent the night inside a narrow range, which leaves the market on track for a flat start. However, some movement is expected to ensue the 8:30 ET release of June Personal Income (Briefing.com consensus 0.3%), Personal Spending (Briefing.com consensus 0.1%), and core PCE Prices (Briefing.com consensus 0.1%). Treasuries held their ground overnight, showing exiguous reaction to Asian economic data, which showed below-consensus Manufacturing PMI readings from Japan and India while China's Caixin Manufacturing PMI beat expectations after the official reading missed estimates on Monday. The Reserve Bank of Australia held its cash rate at 1.50%, as expected. The central bank's statement notable that strength of the Australian dollar is mostly due to the underperformance of the greenback. The S&P 500 futures trade five points above impartial value while raw oil is down 0.6% at $49.89/bbl. The Dollar Index is up 0.1% after ending yesterday's session at its lowest level since May 2016.
  • Yield Check:
  • 2-yr: UNCH at 1.36%
  • 5-yr: +1 bp to 1.84%
  • 10-yr: UNCH at 2.30%
  • 30-yr: UNCH at 2.90%
  • International News:
  • Japan's July Manufacturing PMI 52.1 (expected 52.2; final 52.2)
  • China's July Caixin Manufacturing PMI 51.1 (consensus 50.4; final 50.4)
  • India's Nikkei July Manufacturing PMI 47.9 (expected 50.8; final 50.9)
  • South Korea's July Nikkei Manufacturing PMI 49.1 (last 50.1) Australia's July AIG Manufacturing Index 56.0 (last 55.0) South Korea's July CPI +0.2% month-over-month (last -0.1%); +1.9% year-over-year (consensus 2.0%; final 1.9%). July trade surplus narrowed to KRW10.65 billion from KRW10.77 billion. July Imports +14.5% year-over-year (last 19.8%) and July Exports +19.5% year-over-year (last 13.6%)
  • Eurozone Q2 GDP +0.6% quarter-over-quarter, as expected (last 0.5%); +2.1% year-over-year (consensus 2.4%; final 1.9%). July Manufacturing PMI 56.6 (expected 56.8; final 56.8)
  • Germany's July Manufacturing PMI 58.1 (expected 58.3; final 58.3). July Unemployment Change -9,000 (consensus -5,000; final 6,000) and Unemployment Rate held at 5.7%, as expected
  • Data out Today:
  • June Personal Income (Briefing.com consensus 0.3%), Personal Spending (Briefing.com consensus 0.1%), core PCE Prices (Briefing.com consensus 0.1%) at 8:30 ET
  • June Construction Spending (Briefing.com consensus 0.5%) at 10:00 ET
  • July ISM Index (Briefing.com consensus 56.2) at 10:00 ET July auto and truck sales reported throughout the day
  • 8:11 am Precipio to proffer for sale its common stock and warrants in an underwritten public offering; size not disclosed (PRPO) : The Company intends to exhaust the net proceeds from this offering for the repayment of debt, growth of its sales force, progression of its product development and for working capital and common corporate purposes.

    8:10 am HCP beats by $0.01, reports revs in-line; reaffirms FY17 FFO guidance in-line (HCP) :

  • Reports Q2 (Jun) funds from operations of $0.48 per share, $0.01 better than the Capital IQ Consensus of $0.47; revenues fell 14.8% year/year to $458.9 mln vs the $456.29 mln Capital IQ Consensus.
  • Co reaffirms guidance for FY17, sees FFO of $1.89-1.95 vs. $1.94 Capital IQ Consensus Estimate
  • In addition, co expects 2017 SPP Cash NOI to expand between 2.5-3.5%
  • Tandem debt investment update:

  • During the second quarter, continued challenges in the post-acute/skilled nursing operating environment and tenant-specific headwinds contributed to a decline in the pecuniary performance of the assets underlying their Tandem debt investment
  • "As a result, the impartial value of their collateral, net of the senior mortgage debt, fell below the carrying value of their investment. As Part of their quarterly review process, they recorded a $57 million impairment write-down during the second quarter and reduced the carrying value of their Tandem debt investment to $200 million"
  • "On July 31, subsequent to the aforementioned impairment, they entered into a definitive agreement to sell their Tandem debt investment for $197 million, subject to customary closing conditions. This investment represents their final meaningful exposure to both post-acute/skilled-nursing assets and highly-leveraged mezzanine investments. The transaction is expected to immediate during 2017"
  • 8:09 am Independence Realty Trust beats by $0.01, reports revs in-line; guides FY17 FFO in-line (IRT) :

  • Reports Q2 (Jun) funds from operations of $0.19 per share, $0.01 better than the Capital IQ Consensus of $0.18; revenues rose 2.9% year/year to $39.43 mln vs the $39.43 mln Capital IQ Consensus.
  • Co issues in-line guidance for FY17, sees FFO of $0.73-0.76 vs. $0.74 Capital IQ Consensus Estimate.
  • 8:07 am athenaHealth announces a 'comprehensive review of its operations, cost structure and capital allocation'; has identified approx. $100 mln in cost-savings opportunities and to separate chairman and CEO role (ATHN) :

    In conducting its review, athenahealth has identified ~$100 million in cost-savings opportunities 'that will drive efficiency and targeted investment in the Company's hospital and network services businesses.'

  • athenahealth will provide additional information regarding details of these strategic initiatives, including plans to significantly expand operating margins, in 2018 and thereafter, by its 3Q17 earnings release anticipated in October 2017.
  • athenahealth besides intends to establish the role of president.

  • The Board has retained a leading search hard to fill the president and CFO roles promptly.
  • The Board plans to separate the roles of chairman and CEO and is working to recruit an independent chairman.

  • In addition, the Board has begun a search process to nominate an additional independent director.
  • 8:07 am Meritage beats by $0.22, beats on revs; raises revenue guidance (MTH) :

  • Reports Q2 (Jun) earnings of $0.98 per share, $0.22 better than the Capital IQ Consensus of $0.76; revenues rose 0.5% year/year to $802 mln vs the $760.39 mln Capital IQ Consensus. Home closing revenue was consistent with the prior year, as a 3% expand in average closing cost offset a 2% reduce in home closings compared to the second quarter of 2016. The West and Central regions delivered year-over-year increases of 11% and 9% in home closing revenue, respectively, reflecting strong growth in Arizona and Texas. A 21% decline in East region home closing revenue reflected lower orders over the final three quarters as the region was going through a product library upgrade which delayed the openings of a number of communities.
  • Total orders for the second quarter increased 4% year-over-year due to strong claim in the West and Central regions. Orders increased 30% over the second quarter of 2016 in Texas, as a result of a 24% expand in average lively communities during the quarter and a 5% expand in absorptions (orders per average lively community). Orders increased 2% in the West on a 4% expand in absorptions that was mostly offset by a 3% decline in average community count. East region orders were down 13% compared to the prior year's second quarter, primarily due to a 12% decline in absorptions. Home closing flagrant margin was 17.7% for the second quarter of 2017, compared to 17.3% in the second quarter of 2016. The margin improvement reflects increases in home prices that generally offset increases in land and construction costs, as well as improved leverage of construction overhead expenses.
  • "Housing market conditions remain hardy and Meritage is well-positioned in many of the best markets. They believe that claim for unique homes will continue to be strong, and they are prepared to rob advantage of it," Mr. Hilton concluded. "We are on track to deliver approximately 7,600-8,000 homes and generate estimated total closing revenue of $3.2-3.4 billion for the year (up from $3.1-3.2 bln vs. $3.27 bln consensus). They anticipate pricing power in most markets will allow us to maintain flagrant margins consistent with 2016 while generating ~$230-250 million in pre-tax earnings through a combination of cost management and operating leverage with their anticipated revenue growth."
  • 8:07 am GenMark Diagnostics misses by $0.05, reports revs in-line (GNMK) :

  • Reports Q2 (Jun) loss of $0.37 per share, $0.05 worse than the Capital IQ Consensus of ($0.32); revenues fell 1.2% year/year to $12.36 mln vs the $12.44 mln Capital IQ Consensus.
  • "We are delighted to bask in accomplished several essential goals in the second quarter. Their team achieved FDA 510(k) clearance of the ePlex instrument and Respiratory Pathogen Panel as well as CE notice for replete three of their Blood Culture ID Panels," said Hany Massarany, President and Chief Executive Officer of GenMark. "In addition, they significantly strengthened their poise sheet, which will enable us to bring even more focus to the global commercialization of their ePlex System and its menu expansion," added Massarany.
  • 8:05 am Bayer AG and Rothamsted Research sign strategic framework agreement (BAYRY) :

  • Cos bask in entered into a strategic framework agreement to ameliorate collaborations in scientific areas that will support the development of more customized agronomic solutions for farmers.
  • Building on a track record of collaborations, the partners are forming this strategic alliance to support a digital revolution for detecting and managing biotic threats such as pests, pathogens and weeds more sustainably. Co-ordinated activities, in the laboratory and in the field, will generate the data, know-how, tools and technologies that lighten to support a transition to smarter crop protection.
  • 8:05 am LogMeIn acquires Nanorep replete of the outstanding equity interests in Nanorep for a purchase cost of approximately $45 million; NanoRep is a digital self-service, chatbot and virtual second company (LOGM) : Headquartered in Herzliya, Israel, Nanorep harnesses simulated intelligence and patented natural language processing technologies to create solutions that do self-service more engaging and intuitive. LogMeIn is besides expected to pay up to $5 million in contingent cash payments to inevitable continuing employees of Nanorep upon their achievement of milestone and retention targets over the two-year age following the closing of the transaction.

    8:05 am Fiserv acquires the assets of PCLender, a provider of enterprise internet-based mortgage software and mortgage lending technology solutions; terms not disclosed (FISV) :  

    8:04 am Nant Health: Blue Cross and Blue Shield of Nebraska has signed a three-year contract extension for NaviNet Open (NH) :  

    8:04 am American Railcar Industries misses by $0.04, misses on revs (ARII) :

  • Reports Q2 (Jun) earnings of $0.57 per share, $0.04 worse than the Capital IQ Consensus of $0.61; revenues fell 27.6% year/year to $109 mln vs the $113.62 mln Capital IQ Consensus
  • This reduce was due to decreased revenues in the manufacturing segment, partially offset by slightly increased revenues in the railcar leasing and railcar services segments
  • Lease fleet reaches 12,414 railcars as of June 30, 2017 vs. 10,641 railcars as of June 30, 2016, with 545 railcars added during the second quarter
  • ARI's backlog as of June 30, 2017 was 2,878 railcars with an estimated market value of $270.0 million. Of the total backlog, co currently hope 715 railcars, or 25%, having an estimated market value of $66.5 million, will be placed into their lease fleet.
  • 8:03 am Insperity beats by $0.14, beats on revs; guides Q3 EPS below consensus; guides FY17 EPS above consensus (NSP) :

  • Reports Q2 (Jun) earnings of $0.82 per share, excluding non-recurring items, $0.14 better than the Capital IQ Consensus of $0.68; revenues rose 12.5% year/year to $795.5 mln vs the $778.88 mln Capital IQ Consensus. Adjusted EBITDA increased 30% over the second quarter of 2016 to $33.3 million.
  • Co issues downside guidance for Q3, sees EPS of $0.94-1.00, excluding non-recurring items, vs. $1.02 Capital IQ Consensus Estimate.
  • Co issues raised guidance for FY17, sees EPS of $4.47-4.60 from $4.30-4.44, excluding non-recurring items, vs. $4.33 Capital IQ Consensus Estimate.
  • 8:02 am ProAssurance sees prelim Q2 $0.38-0.41 vs $0.54 Capital IQ Consensus assay (PRA) :  Co states, "We believe flagrant premiums written in the quarter will be approximately $206.0 million and net earned premium for the quarter will be approximately $180.5 million. They anticipate favorable loss development will be in the range of $28.5 million to $30.0 million and they project their consolidated combined ratio to be in a range between 95% and 97% for the quarter."

    8:02 am Sabre reports EPS in-line, revs in-line; reaffirms FY17 EPS and revenue guidance but now expects EPS to be in lower half of guidance; announces reorganization, 9% headcount reduction (SABR) :

  • Reports Q2 (Jun) earnings of $0.35 per share, excluding non-recurring items, in-line with the Capital IQ Consensus of $0.35; revenues rose 6.6% year/year to $900.7 mln vs the $895.1 mln Capital IQ Consensus.
  • Co reaffirms guidance for FY17, sees EPS of $1.31-1.45, excluding non-recurring items, vs. $1.39 Capital IQ Consensus Estimate; sees FY17 revs of $3.54-3.62 bln vs. $3.58 bln Capital IQ Consensus Estimate. However, Sabre now expects that 2017 EPS results will likely be in the lower half of this guidance. Strategic prioritization has led Sabre to reduce its expectations for 2017 cap-ex and capitalized implementation costs by $50 million in aggregate.
  • Co announces an initiative to streamline and focus the industry through reorganizing inevitable functions, reducing layers of management, and lowering costs to enable a more nimble, faster touching and focused organization. The initiative is expected to reduce global headcount by approximately 9%. At replete run-rate, the program is anticipated to result in approximately $110 mln of annual savings. Sabre expects the program to be neutral to 2017 Free Cash Flow. Cost savings under the initiative are expected to achieve replete run-rate in 2018.
  • 8:02 am IPG Photonics beats by $0.26, beats on revs; guides Q3 EPS above consensus, revs above consensus (IPGP) :

  • Reports Q2 (Jun) earnings of $1.91 per share, $0.26 better than the Capital IQ Consensus of $1.65; revenues rose 46.1% year/year to $369.37 mln vs the $333.06 mln Capital IQ Consensus.
  • Co issues upside guidance for Q3, sees EPS of $1.70-1.90 vs. $1.59 Capital IQ Consensus Estimate; sees Q3 revs of $350-375 mln vs. $318.62 mln Capital IQ Consensus Estimate.
  • Demand for their core products, particularly high-power, kilowatt-scale fiber lasers, has never been stronger. Their leadership position within this fast-growing market drove record order activity in the quarter, resulting in a book-to-bill ratio above one. Based on these trends and the strength of their current backlog, they believe they are in excellent position to deliver another strong quarter in three months
  • Year-to-date bookings bask in exceeded their expectations, pointing to strong revenue growth in 2017. Based on first half outperformance and current backlog, they are now targeting approximately 32% to 34% revenue growth for the replete year. Their fourth quarter performance will be driven by order activity through the conclude of the third quarter and during the fourth quarter, for which their visibility is low. Given the magnitude of outperformance during the first half of the year, they believe it is prudent to assume a lower growth rate in the fourth quarter due to more challenging comparisons and an expected slowdown in spending related to typical seasonality in China and the consumer electronics investment cycle. Should this anticipated spending slowdown fail to materialize at a level consistent with historic trends, this could result in upside to their replete year guidance range
  • 8:01 am S&P futures vs impartial value: +5.30. Nasdaq futures vs impartial value: +20.40. (:WRAPX) :

    It appears that the stock market will open Tuesday's session in the green following yesterday's mixed finish. The S&P 500 futures currently trade five points, or 0.2%, above impartial value.

    Apple (AAPL 149.00, +0.27), the S&P 500's largest component by market cap, will release its latest earnings report following today's closing bell. Investors will be looking for further details on the much-anticipated iPhone 8, which is expected to be released later this year. AAPL shares currently hold a year-to-date gain of 28.4%.

    The Personal Income and Personal Spending Report for June, which will cross the wires at 8:30 ET, is the highlight on today's economic calendar. The Briefing.com consensus expects that personal income and personal spending will expand by 0.3% and 0.1%, respectively. The report will besides comprehend the core PCE cost Index (Briefing.com consensus 0.1%).

    In addition, investors will besides receive the June Construction Spending Report (Briefing.com consensus 0.5%) and the July ISM Index (Briefing.com consensus 56.2), both of which will be released at 10:00 ET. Auto and truck sales will be released throughout the day.

    U.S. Treasuries are trading flat for the second day in a row, leaving the benchmark 10-yr yield unchanged at 2.29%. Meanwhile, the U.S. Dollar Index (92.82, +0.15) is up 0.2% and raw oil is down 0.4% at $49.98/bbl. The commodity enters today's session on a six-session winning streak. 

    In U.S. corporate news:

  • Pfizer (PFE 33.38, +0.22): +0.7% after better than expected earnings outweighed lower than expected revenues.
  • Sprint (S 8.20, +0.22): +2.8% after beating bottom-line estimates and raising its profit guidance.
  • Under Armour (UAA 19.61, -0.41): -2.1% after downbeat guidance overshadowed better than expected earnings and revenues.
  • Reviewing overnight developments:

  • Equity indices in the Asia-Pacific region ended Tuesday on a higher note. Japan's Nikkei +0.3%, Hong Kong's Hang Seng +0.8%, China's Shanghai Composite +0.6%, India's Sensex +0.2%.
  • In economic data:
  • Japan's July Manufacturing PMI 52.1 (expected 52.2; final 52.2)
  • China's July Caixin Manufacturing PMI 51.1 (consensus 50.4; final 50.4)
  • India's Nikkei July Manufacturing PMI 47.9 (expected 50.8; final 50.9)
  • South Korea's July Nikkei Manufacturing PMI 49.1 (last 50.1)
  • Australia's July AIG Manufacturing Index 56.0 (last 55.0)
  • South Korea's July CPI +0.2% month-over-month (last -0.1%); +1.9% year-over-year (consensus 2.0%; final 1.9%). July trade surplus narrowed to KRW10.65 billion from KRW10.77 billion. July Imports +14.5% year-over-year (last 19.8%) and July Exports +19.5% year-over-year (last 13.6%)
  • In news:
  • Regional economic data included below-consensus Manufacturing PMI readings from India and Japan while China's Caixin Manufacturing PMI beat expectations.
  • The People's Bank of China reportedly uncovered operational violations at 40 Chinese banks. The banks bask in up to six months to rectify the issues.
  • In Japan, Chief Cabinet Secretary Yoshihide Suga confirmed that Prime Minister Shinzo Abe plans to reshuffle his cabinet on August 3.
  • The Reserve Bank of Australia left its cash rate unchanged at 1.50%, as expected. The central bank notable that the relative strength of the Australian dollar results from weakness in the U.S. dollar.
  • The Reserve Bank of India will meet overnight.
  • Major European indices trade higher across the board while the euro (1.1814) has shed 0.2% against the dollar after hitting a 19-month towering against the greenback yesterday afternoon. Germany's DAX +0.3%, France's CAC +0.5%, UK's FTSE +0.5%.
  • In economic data:
  • Eurozone Q2 GDP +0.6% quarter-over-quarter, as expected (last 0.5%); +2.1% year-over-year (consensus 2.4%; final 1.9%). July Manufacturing PMI 56.6 (expected 56.8; final 56.8)
  • Germany's July Manufacturing PMI 58.1 (expected 58.3; final 58.3). July Unemployment Change -9,000 (consensus -5,000; final 6,000) and Unemployment Rate held at 5.7%, as expected
  • UK's July Manufacturing PMI 55.1 (expected 54.4; final 54.2). July Nationwide HPI +0.3% month-over-month (expected -0.1%; final 1.1%); +2.9% year-over-year (consensus 2.7%; final 3.1%)
  • France's July Manufacturing PMI 54.9 (expected 55.4; final 55.4)
  • Italy's July Manufacturing PMI 55.1 (consensus 55.2; final 55.2)
  • Spain's July Manufacturing PMI 54.0 (expected 54.5; final 54.7)
  • In news:
  • British Chancellor Philip Hammond said Brexit will not be postponed or delayed, but the balancing of the UK's budget may be delayed.
  • 7:50 am Libbey misses by $0.21, reports revs in-line; reaffirms FY17 Outlook (LBY) :

  • Reports Q2 (Jun) loss of $0.04 per share, $0.21 worse than the Capital IQ Consensus of $0.17; revenues fell 5.0% year/year to $197.5 mln vs the $198.29 mln two analyst estimate.
  • Net sales in the U.S. and Canada segment were lower due to softer sales in the retail and business-to-business channels, which were down approximately 10 percent and 2 percent, respectively. U.S. and Canada foodservice net sales were flat versus prior year, despite volume increases in the channel.
  • In Latin America, net sales declined as a result of lower net sales across replete channels, primarily due to lower volume in the retail channel. Decreased volume in the business-to-business channel was offset by favorable cost and mix.
  • Net sales in the EMEA segment decreased primarily as a result of unfavorable currency.
  • Net sales in Other were down as a result of softer sales in China.
  • FY17 Outlook
  • Affirmed its previous full-year 2017 outlook, but indicated that it expects Adjusted EBITDA margin to be near the low conclude of its previously provided 11 percent to 13 percent range. 
  • Net sales decline in the low-to-mid single digits, compared to the replete year 2016, on a reported basis, with continued currency headwinds    
  • Capital expenditures of approximately $50 million.
  • "Second quarter sales results were in line with their expectations, as an intensely competitive pricing environment continues to linger on a global basis," said Chairman and Chief Executive Officer William Foley. "We remain confident that they are taking the preempt measures to ameliorate the long-term performance of their business. We're seeing indications that inevitable pricing initiatives they implemented final quarter are taking hold, and that their unique product initiatives are dawn to gain traction in the marketplace. We're besides very pleased that their unique e-commerce platform launched on time and on budget in mid-July."
  • 7:46 am On The Wires (:WIRES) :

  • Mateon Therapeutics (MATN) has completed enrollment of more than 80 patients in the side 2 portion of its FOCUS study evaluating CA4P in combination with bevacizumab (Avastin) and physician's preference chemotherapy for the treatment of platinum-resistant ovarian cancer.
  • Madrigal Pharmaceuticals (MDGL) has completed patient enrollment of 125 patients, exceeding its targeted enrollment of 117 patients, in its side 2 proof-of-concept study evaluating MGL-3196 for the treatment of non-alcoholic steatohepatitis (NASH). MGL-3196 is a first-in-class, oral, once-daily, liver-directed, thyroid hormone receptor (THR) -selective agonist medication. The primary endpoint is the reduction of liver fat, assessed by MRI-PDFF, at 12 weeks. The co expects to report top-line results by year-end.
  • Mallinckrodt Pharmaceuticals (MNK) confirmed inclusion of the first patient in the company's side 4 registry assessing the exhaust of INOMAX (nitric oxide) gas for inhalation for premature (less than 34 weeks gestational age) neonates versus term and near-term neonates (greater than 34 weeks gestational age).
  • 7:46 am Jacobs signed a global Enterprise Framework Agreement renewal with Shell Oil Company to provide concept, front-end engineering, circumstantial design, procurement, project management, construction management and construction services for Shell projects globally (JEC) :  

    7:40 am Intellia Therapeutics misses by $0.03, beats on revs (NTLA) :

  • Reports Q2 (Jun) loss of $0.45 per share, $0.03 worse than the Capital IQ Consensus of ($0.42); revenues rose 40.5% year/year to $5.9 mln vs the $5.83 mln Capital IQ Consensus. 
  • "We are very excited that their initial non-human primate data in vivo continue to validate their mRNA delivery technology. These preclinical data accelerate their momentum as they forward the development of potential therapies to treat patients with towering unmet medical needs."
  • Primary uses of capital will continue to be research and development programs, laboratory and related supplies, compensation and related expenses, legal and other regulatory expenses, patent prosecution, filing and maintenance costs for their licensed intellectual property, and common overhead costs. During 2017, the company expects expenses to continue to expand compared to prior periods relating to their ongoing activities, particularly as research and development and preclinical activities assemble further momentum toward human clinical trials, and they spend a replete year occupying their unique office and laboratory facility, which they began to occupy in the fourth quarter of 2016. hope that the cash and cash equivalents as of June 30, 2017, as well as technology access and research funding from Novartis and Regeneron, will enable Intellia to fund operating expenses and capital expenditures through mid-2019, excluding any potential milestone payments or extension fees received under their collaboration agreements with Novartis and Regeneron.
  • 7:37 am Erin Energy announces the arrival of the Pacific Bora drilling rig to the Oyo territory offshore Nigeria, expected to double its production (ERN) :

    Erin Energy plans to exhaust Pacific Bora to drill the Oyo-9 well (Oyo-9) on the Oyo territory in deepwater offshore Nigeria.

  • The Company expects to commence drilling of Oyo-9 in ~10 days and the well to add an additional 6,000 to 7,000 barrels per day.
  • 7:37 am Zynerba Pharma misses by $0.05; Top-line side 2 results for STAR 1 trial in epilepsy and STOP trial in osteoarthritis remain on track for reporting in August 2017 (ZYNE) :

  • Reports Q2 (Jun) loss of $0.64 per share, $0.05 worse than the Capital IQ Consensus of ($0.59). 
  • "We hope to promulgate top-line results from the STAR 1 trial soon, followed by top-line data from the STOP trial later this month; and they remain on track to report top-line results from the FAB-C delicate X study in September," said Armando Anido, Chairman and Chief Executive Officer. "We besides met a significant milestone during the quarter in initiating the side 1 program for ZYN001, a pro-drug of THC delivered via patch, and hope to initiate their side 2 program by the conclude of this year. With two clinical stage assets, Zynerba is well-positioned to address a number of serious unmet medical needs."
  • The Company believes that the current cash and cash equivalent position of $70.2 million is sufficient to develop five side 3-ready programs and, assuming support from the FDA to rush forward, initiate at least one side 3 program and fund operations and capital requirements into 2019.
  • 7:36 am Affimed Therapeutics beats by $0.02, misses on revs (AFMD) :

  • Reports Q2 (Jun) loss of 0.18 per share, 0.02 better than the Capital IQ Consensus of (0.20); revenues fell 75.4% year/year to 0.51 mln vs the 1.31 mln Capital IQ Consensus.
  • "We are encouraged by the progress of their clinical programs, in particular touching into the expansion side of their AFM13 combination trial with Keytruda," said Dr. Adi Hoess, CEO of Affimed. "In their preclinical programs addressing the medical necessity in solid tumors and multiple myeloma, they bask in designed and characterized well-differentiated molecules and determined advantages in safety and potency."
  • 7:35 am Cummins misses by $0.03, beats on revs; guides FY17 revs above consensus (CMI) :

  • Reports Q2 (Jun) earnings of $2.53 per share, $0.03 worse than the Capital IQ Consensus of $2.56; revenues rose 12.1% year/year to $5.08 bln vs the $4.8 bln Capital IQ Consensus.
  • Co issues upside guidance for FY17, sees FY17 revs of +9-11% (Approx $19.08-19.43 bln) vs. $18.52 bln Capital IQ Consensus Estimate.
  • Cummins expects replete year 2017 revenues to be up 9 to 11 percent, higher than the prior forecast of up 4 to 7 percent.
  • EBIT is expected to be in the range of 11.75 to 12.5 percent of sales, unchanged from prior guidance. This forecast excludes the impact of their unique Eaton Cummins Automated Transmission Technologies joint venture.
  • 7:33 am Myers Industries beats by $0.04, reports revs in-line; reaffirms FY17 revs outlook (MYE) :

  • Reports Q2 (Jun) earnings of $0.17 per share, excluding non-recurring items, $0.04 better than the Capital IQ Consensus of $0.13; revenues fell 1.2% year/year to $142.3 mln vs the $142.95 mln Capital IQ Consensus.
  • The Company continues to anticipate that total revenue will be flat on a constant currency basis in fiscal year 2017 as compared to the prior year.
  • 7:33 am TG Therapeutics and FDA gain agreement regarding a Special Protocol Assessment on the design of two side 3 clinical trials for TG-1101 for the treatment of relapsing forms of Multiple Sclerosis (TGTX) :

    The SPA provides agreement that the two side 3 trial designs adequately address objectives that, if met, would support the regulatory submission for approval of TG-1101.

  • Co states, "The early data from their side 2 clinical trial, the highly successful pivotal results for the anti-CD20 monoclonal antibody ocrelizumab in MS, and the substantial safety data generated in their oncology program, gives us a towering level of confidence in the potential for a successful outcome. Their team in concert with their CRO has been hard at work on the logistics and the launch of these side 3 trials on a global basis, and they spy forward to enrolling their first patient before the conclude of the summer."
  • 7:33 am Sprint beats by $0.10, reports revs in-line; raises profit guidance (S) :

  • Reports Q1 (Jun) earnings of $0.05 per share, $0.10 better than the Capital IQ Consensus of ($0.05); revenues rose 1.8% year/year to $8.16 bln vs the $8.14 bln Capital IQ Consensus, its fourth consecutive quarter of year-over-year growth, and 88,000 postpaid phone net additions, its eighth consecutive quarter of net additions. Postpaid phone flagrant additions besides grew year-over-year for the sixth consecutive quarter and were the highest first-quarter result in five years. "Sprint reached an essential milestone this quarter by returning to profitability for the first time in three years," said Sprint CEO Marcelo Claure. "This represents the progress of a turnaround journey that has delivered improvements in postpaid phone and prepaid customer growth, a return to top-line growth, and a significantly transformed cost structure."
  • Sprint continued to do progress on its multiyear design to transform the way it does industry and ameliorate its cost structure. The company delivered nearly $370 million of combined year-over-year reductions in cost of services and SG&A expenses in the quarter, bringing the total reduction during the final nine quarters to nearly $4 billion. The ongoing cost-reduction program contributed to a return to profitability this quarter, as the company reported net income for the first time in three years. Excluding the after-tax profit of non-recurring items in the quarter, Sprint would bask in reported net income of more than $150 million, demonstrating the improved underlying trends of the business. Sprint expects an additional $1.3 billion to $1.5 billion of year-over-year net reductions in cost of services and SG&A expenses in fiscal year 2017. Although the flagrant reductions are expected to be higher, the company plans to reinvest some of the savings into future growth initiatives.
  • The company is increasing the low conclude of its previous Adjusted EBITDA* expectations and now expects $10.8 billion to $11.2 billion for fiscal year 2017. The previous expectation was $10.7 billion to $11.2 billion. The company is increasing the low conclude of its previous operating income expectations and now expects operating income of $2.1 billion to $2.5 billion. The previous expectation was $2 billion to $2.5 billion. The company continues to hope cash capital expenditures, excluding devices leased through circuitous channels, of $3.5 billion to $4 billion.
  • 7:33 am CDK Global beats by $0.01, beats on revs; guides FY18 EPS above consensus (CDK) :

  • Reports Q4 (Jun) earnings of $0.55 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of $0.54; revenues rose 4.3% year/year to $565.4 mln vs the $556.68 mln Capital IQ Consensus.
  • Co issues upside guidance for FY18, sees EPS of $2.90-3.00, excluding non-recurring items, vs. $2.93 Capital IQ Consensus Estimate.
  • "I am pleased with the results of their fiscal year and benefits delivered by executing their transformation plan. Adjusted EBITDA margin expansion of 550 basis points in fiscal 2017, combined with the 370 basis points of expansion achieved in fiscal 2016, puts us on track to achieve their transformation goals," said Brian MacDonald, chief executive officer. "By improving their products and processes and focusing on their dealer customers, they are making solid progress. Based on successes to date, they hope to exceed the fiscal 2018 adjusted EBITDA target of 35%."
  • 7:32 am Eyegate Pharmaceuticals has enrolled its first patient in the Company's side 2b clinical trial of its EGP-437 combination product (EYEG) :

    The EyeGate II Delivery System and EGP-437 combination product, is being evaluated for the treatment of throe and inflammation in patients having undergone cataract surgery with implantation of a monofocal posterior chamber IOL.  

  • As announced in the first quarter of 2017, EyeGate and Valeant (VRX) entered into an exclusive, worldwide licensing agreement through which EyeGate has granted a subsidiary of Valeant exclusive, worldwide commercial and manufacturing rights to the EGP-437 combination product candidate for the treatment of post-operative ocular inflammation and throe in ocular surgery patients.
  • 7:31 am Flex Pharma initiates side 2 CONMEND trial in the US, will evaluate FLX-787 in patients with motor neuron disease, focused on ALS, who suffer from painful, debilitating cramps; co expects to report topline results from this study in the middle of 2018 (FLKS) :

    The co has initiated a side 2 randomized, controlled, double-blinded, parallel design trial in the US, referred to as the COMMEND trial.

  • The COMMEND trial will evaluate FLX-787, the Company's co-activator of TRPA1 and TRPV1, in patients with motor neuron disease, focused on ALS, who suffer from painful, debilitating cramps.
  • The FDA has granted FLX-787 swiftly Track designation for the treatment of severe muscle cramps associated with ALS.
  • The Company expects to report topline results from this study in the middle of 2018.
  • The Company besides intends to initiate a side 2 clinical trial in CMT this quarter.
  • 7:29 am Penske Auto commences $300 mln offering of Senior Subordinated Notes due 2020 (PAG) : The company intends to exhaust the net proceeds of this offering to repay amounts currently outstanding under the company's U.S. credit agreement and for common working capital purposes.

    7:25 am Martin Marietta misses by $0.10, misses on revs; guides FY17 revs in-line (MLM) :

  • Reports Q2 (Jun) earnings of $2.25 per share, $0.10 worse than the Capital IQ Consensus of $2.35; revenues rose 8.8% year/year to $996.3 mln vs the $1014.78 mln Capital IQ Consensus.
  • Building Materials net sales of $931.7 million compared with $856.6 million, an expand of 8.8%, and Magnesia Specialties net sales of $64.6 million compared with $58.8 million, an expand of 9.7%
  • Consolidated flagrant profit of $274.1 million compared with $247.4 million, an expand of 10.8%
  • Co issues in-line guidance for FY17, sees FY17 revs of $3.75-3.95 bln vs. $3.93 bln Capital IQ Consensus Estimate.
  • Infrastructure market to expand mid-single digits.
  • Nonresidential market to expand in the low- to mid-single digits.
  • Residential market to expand in the mid- to high-single digits.
  • ChemRock/Rail market to remain stable.
  • 2017 consolidated net sales exclude $390 million related to estimated interproduct sales.
  • Ward Nye, Chairman, President and CEO of Martin Marietta, stated, "Our record second-quarter results reflect improved sales, flagrant profit and earnings from operations in each reportable group, underscoring the breadth of their industry and their capacity to capitalize on the ongoing recovery in construction activity. Positive residential and nonresidential activity drove results, along with pricing improvements across their aggregates product line, led by the Southeast Group's 10.6 percent increase. They overcame challenging operating conditions in several key states, as near-record levels of precipitation in North Carolina, South Carolina, Georgia and Florida negatively impacted aggregates shipments and operating efficiencies in their historically most profitable geographic areas. Looking ahead, they are optimistic about the remnant of 2017 and beyond due to increased momentum across almost their entire geographic footprint and the positive near- and medium-term outlooks expressed by their customers."
  • 7:20 am Intesa Sanpaolo reports H1 results (ISNPY) :

  • Net income was 1,738 million excluding the aforementioned public contribution and 2,198 million excluding, in addition, levies and other charges concerning the banking industry.
  • Net interest income in Q2 2017 up 0.6% on Q1 2017, and in H1 2017 up 1.5% on H1 2016 when excluding the impact of the devaluation of the Egyptian currency.
  • The credit property trend improved. the past 21 months recorded a 10 billion flagrant npl stock reduction, which was achieved at no extraordinary cost to shareholders. in q2 2017, flagrant npl inflow from performing loans was at its lowest since the creation of intesa sanpaolo.
  • 7:18 am Lifepoint Hospitals beats by $0.06, misses on revs; guides FY17 EPS lower, revs below consensus (LPNT) :

  • Reports Q2 (Jun) earnings of $0.96 per share, excluding non-recurring items, $0.06 better than the Capital IQ Consensus of $0.90; revenues rose 0.2% year/year to $1.59 bln vs the $1.64 bln Capital IQ Consensus.
  • William F. Carpenter III, Chairman and Chief Executive Officer of LifePoint Health, said, "We are pleased to deliver another quarter of solid results with EBITDA growth and expanded margins both year-over-year and sequentially. Their longstanding operating discipline continues to be integral to their success even while the volume environment remains challenging. They are successfully integrating recently acquired hospitals and health systems and remain committed to their strategic priorities of property and service, growth, operational excellence and talent development at every location to drive long-term value for their shareholders."
  • Co issues guidance for FY17, sees EPS of $3.92-$4.20 vs. $4.19 Capital IQ Consensus assay and prior guidance of $4.05-$4.34; sees FY17 revs of $6.425-$6.500 bln vs. $6.55 bln Capital IQ Consensus assay and prior guidance of $6.50-$6.60 bln.
  • 7:18 am European Markets Update: DAX +0.3%, CAC +0.5%, FTSE +0.5% (:SUMRX) :

    Major European indices trade higher across the board while the euro (1.1814) has shed 0.2% against the dollar after hitting a 19-month towering against the greenback yesterday afternoon. British Chancellor Philip Hammond said Brexit will not be postponed or delayed, but the balancing of the UK's budget may be delayed.

  • In economic data:
  • Eurozone Q2 GDP +0.6% quarter-over-quarter, as expected (last 0.5%); +2.1% year-over-year (consensus 2.4%; final 1.9%). July Manufacturing PMI 56.6 (expected 56.8; final 56.8)
  • Germany's July Manufacturing PMI 58.1 (expected 58.3; final 58.3). July Unemployment Change -9,000 (consensus -5,000; final 6,000) and Unemployment Rate held at 5.7%, as expected
  • UK's July Manufacturing PMI 55.1 (expected 54.4; final 54.2). July Nationwide HPI +0.3% month-over-month (expected -0.1%; final 1.1%); +2.9% year-over-year (consensus 2.7%; final 3.1%)
  • France's July Manufacturing PMI 54.9 (expected 55.4; final 55.4)
  • Italy's July Manufacturing PMI 55.1 (consensus 55.2; final 55.2)
  • Spain's July Manufacturing PMI 54.0 (expected 54.5; final 54.7)
  • ---Equity Markets---

  • Germany's DAX is higher by 0.3% with most components trading in the green. Lufthansa has spiked 2.6% while Prosiebensat 1, Heidelbergcement, and Infineon are up between 1.0% and 1.2%. BMW, Daimler, and Volkswagen expose gains between 0.6% and 1.0%. Adidas is the weakest component, falling 0.7%.
  • France's CAC trades up 0.5% with heavyweights among the leaders. Peugeot, Airbus Group, Renault, Louis Vuitton, and Total bask in added between 1.1% and 1.5%. A handful of consumer names lag with L'Oreal, Danone, and Pernod Ricard shedding between 0.2% and 1.1%.
  • UK's FTSE has climbed 0.5%. Rolls-Royce has surged 9.4% in reaction to upbeat earnings while BP has climbed 2.7% after it too beat estimates. Consumer stocks dote Paddy Power, Imperial Brands, Taylor Wimpey, Burberry, and British American Tobacco expose gains between 0.9% and 1.7%. On the downside, select miners dote Fresnillo, Anglo American, and Randgold Resources expose losses between 0.6% and 2.5%.
  • 7:17 am Broadwind Energy reports EPS in-line, revs in-line; guides Q3 EPS below two analyst estimate, revs below consensus (BWEN) :

  • Reports Q2 (Jun) loss of $0.05 per share, in-line with the Capital IQ Consensus of ($0.05); revenues were unchanged from the year-ago age at $43.4 mln.
  • Co issues downside guidance for Q3, sees EPS of ($0.15)-(0.17), excluding non-recurring items, vs. $0.02 two analyst estimate; sees Q3 revs of $30 mln vs. $41.25 mln Capital IQ Consensus Estimate.
  • Q4 outlook highly uncertain due to change in tower procurement and engineering practices.
  • 7:16 am ACCO Brands beats by $0.05, misses on revs; raises FY17 EPS guidance to be at the towering conclude of prior range, in-line, reaffirms revs in-line (ACCO) :

  • Reports Q2 (Jun) earnings of $0.31 per share, excluding non-recurring items, $0.05 better than the Capital IQ Consensus of $0.26; revenues rose 19.5% year/year to $490 mln vs the $497.17 mln Capital IQ Consensus.
  • Co raises 2017 EPS guidance....
  • Co expects FY17 EPS to be at the towering conclude of its prior adjusted EPS range, at $1.07-1.10, excluding non-recurring items, vs. $1.08 Capital IQ Consensus Estimate; reaffirms FY17 revenue growth expectation of 22-26%, which equates to roughly $1.90-1.96 vs. $1.94 bln Capital IQ Consensus Estimate.
  • 7:15 am Endurance International misses by $0.11, reports revs in-line; updates guidance (EIGI) :

  • Reports Q2 (Jun) GAAP loss of $0.29 per share, $0.11 worse than the Capital IQ GAAP consensus assay of ($0.18); revenues rose 0.5% year/year to $292.26 mln vs the $289.4 mln Capital IQ Consensus.
  • Total subscribers on platform at June 30, 2017 were approximately 5.217 million, compared to approximately 5.480 million subscribers at June 30, 2016 and 5.304 million subscribers at March 31, 2017.
  • Adjusted EBITDA for the second quarter of 2017 was $82.5 million, an expand of 7 percent compared to $76.9 million for the second quarter of 2016.
  • Updated Guidance:
  • Co sees GAAP revenue +5-5.5% (Prior 4-5%)
  • Co sees Adjusted EBITDA +14-16% (Prior +12-14%)
  • Co sees Free cash stream +25% (Prior +35%)
  • 7:15 am Scotts Miracle-Gro beats by $0.12, beats on revs; reaffirms FY17 guidance; expects to rasie dividend in near future (SMG) :

  • Reports Q3 (Jun) earnings of $2.63 per share, $0.12 better than the Capital IQ Consensus of $2.51; revenues rose 8.5% year/year to $1.08 bln vs the $1.06 bln Capital IQ Consensus. U.S. Consumer increased 5 percent to $792.2 million from $756.7 million. Europe Consumer sales declined 3 percent, but increased 2 percent when excluding the impact of alien exchange rates, to $93.2 million. Sales in the "Other" segment increased 36 percent to $192.6 million due to the acquisitions of Botanicare and Gavita as well as year-over- year growth within The Hawthorne Gardening Company.
  • Co reaffirms guidance for FY17, sees EPS of $4.00-4.20, excluding non-recurring items, vs. $4.13 Capital IQ Consensus Estimate; sees FY17 revs of +3-4% to $2.92-2.95 bln vs. $2.93 bln Capital IQ Consensus Estimate. 
  • The Company now expects to complete the pending sale of its European and Australian businesses in the fourth quarter and anticipates lowering its guidance for Non-GAAP adjusted earnings by ~$0.20 per share at that time. "Once this pending divestiture is behind us, the material changes in reconfiguration of their portfolio will largely be behind us," Hagedorn said. "Where appropriate, they will continue to quest tuck-in acquisitions that complement their remaining portfolio, however, their warp going forward will be to return cash to shareholders. They hope to expand their quarterly dividend in the near future and will continue to be an lively acquirer of their shares." 
  • 7:15 am Lexicon Pharma beats by $0.11, misses on revs (LXRX) :

  • Reports Q2 (Jun) loss of $0.33 per share, $0.11 better than the Capital IQ Consensus of ($0.44); revenues fell 40.3% year/year to $12 mln vs the $18.34 mln Capital IQ Consensus.
  • Anticipated Upcoming Milestones September 11-15, 2017 -- Two oral presentations (inTandem2 and JDRF studies) and two poster presentations (dose ranging and in Tandem studies) at the 53rd Annual Meeting of the European Association for the Study of Diabetes (:EASD) in Lisbon. Q3 2017 - Secondary endpoint data from inTandem. Q3 2017 - Pooled continuous glucose monitoring (:CGM) data from inTandem1 and inTandem.
  • 7:13 am On The Wires (:WIRES) :

  • Magellan Health (MGLN) has launched a hemophilia management program in collaboration with Health unique England, a non-profit health design serving the commercial, Medicaid and Medicare markets.
  • Spectrum Pharmaceuticals (SPPI) has completed enrollment with 405 patients randomized in the ROLONTIS side 3 forward pivotal study under a Special Protocol Assessment (SPA) with the FDA. The study is evaluating the safety and efficacy of ROLONTIS in the management of chemotherapy-induced neutropenia in patients with breast cancer. Enrollment has been completed ahead of schedule. The Company plans to promulgate topline data in Q1 2018 and file a Biologics License Application (:BLA) next year.
  • Acceleron Pharm (XLRN) announced that the first patient has been treated in a side 2 clinical trial of ACE-083, the Company's locally acting muscle agent, for the treatment of patients with Charcot-Marie-Tooth disease (CMT).
  • 7:12 am Government Properties Income Trust beats by $0.01, beats on revs (GOV) :

  • Reports Q2 (Jun) funds from operations of $0.60 per share, $0.01 better than the Capital IQ Consensus of $0.59; revenues rose 9.1% year/year to $69.89 mln vs the $69.08 mln Capital IQ Consensus.
  • Completed 288,428 Square Feet of Leasing in the Second Quarter for a 13.5% expand in Rents.
  • Occupancy was 95.0% at Quarter End, Up 80 Basis Points Year Over Year.
  • Announced Agreement to Acquire First Potomac Realty Trust for Approximately $1.4 Billion.
  • "Government Properties Income Trust achieved solid leasing results during the second quarter of 2017. They entered into unique and renewal leases for over 288,000 square feet of space for rents that were 13.5% higher than previous rents for the very space. They besides announced their planned strategic acquisition of First Potomac Realty Trust and began to implement their long term financing and industry repositioning plans associated with that acquisition by raising $494 million of net proceeds from the sale of common equity and the issuance of $300 million aggregate principal amount of senior unsecured notes due 2022."
  • 7:11 am Oxford Immunotec misses by $0.42, beats on revs; guides Q3 revs in-line; raises FY17 revs guidance in-line (OXFD) :

  • Reports Q2 (Jun) loss of $0.74 per share, $0.42 worse than the two analyst assay of ($0.32); revenues rose 35.9% year/year to $26.1 mln vs the $25.05 mln Capital IQ Consensus.
  • Co issues in-line guidance for Q3, sees Q3 revs of $29.5-$30.5 mln vs. $30.38 mln Capital IQ Consensus Estimate.
  • Co issues in-line guidance for FY17, sees FY17 revs of $103.0-$106.0 mln vs. $103.99 mln Capital IQ Consensus assay and prior guidance of $102.0-$105.0 mln.
  • 7:11 am IDEXX Labs beats by $0.02, beats on revs; raises FY17 guidance (IDXX) :

  • Reports Q2 (Jun) earnings of $0.87 per share, excluding non-recurring items, $0.02 better than the Capital IQ Consensus of $0.85; revenues rose 9.1% year/year to $508.9 mln vs the $502.44 mln Capital IQ Consensus.
  • Co issues raised guidance for FY17, sees EPS of $3.12-3.22 from $2.95-3.11 vs. $3.07 Capital IQ Consensus Estimate; raises FY17 revs to $1.945-1.965 bln from $1.925-1.95 bln vs. $1.94 bln Capital IQ Consensus Estimate.
  • Gross profits increased 12%, and flagrant margin increased to 57.5% from 55.8% in the prior year period.
  • 7:11 am Phillips 66 Partners misses by $0.07, reports revs in-line (PSXP) :

  • Reports Q2 (Jun) earnings of $0.61 per share, $0.07 worse than the Capital IQ Consensus of $0.68; revenues were unchanged from the year-ago age at $234 mln.
  • Adjusted EBITDA was $170 million in the second quarter, compared with $155 million in the prior quarter.
  • The Sand Hills Pipeline expansion continues to progress. The project will expand capacity from 280,000 barrels per day (:BPD) to 365,000 BPD, with an expected in-service date by the conclude of 2017. In addition, DCP Midstream, the operator of the pipeline, has announced plans to further expand the line to approximately 450,000 BPD. Phillips 66 Partners owns a one-third interest in this joint venture.
  • 7:11 am Colliers beats by $0.08, beats on revs (CIGI) :

  • Reports Q2 (Jun) earnings of $0.76 per share, excluding non-recurring items, $0.08 better than the Capital IQ Consensus of $0.68; revenues rose 12.8% year/year to $544.2 mln vs the $515.45 mln Capital IQ Consensus.
  • 7:10 am Incyte misses by $0.02, beats on revs; raises sales guidance (INCY) :

  • Reports Q2 (Jun) loss of $0.06 per share, $0.02 worse than the Capital IQ Consensus of ($0.04); revenues rose 32.5% year/year to $326.4 mln vs the $318.45 mln Capital IQ Consensus. Net product revenues of Jakafi were $276 million as compared to $208 million for the very age in 2016, representing 33 percent growth.
  • Raises Jakafi net rev to $1.09-1.12 bln from $1.02-1.07 bln; reaffirms Iclusig $60-65 mln. Proof-of-concept data for the combination of epacadostat plus PD-1 inhibition presented at the American Society of Clinical Oncology Annual Meeting (:ASCO) 2017 across multiple tumor types; expanded side 3 program on track for planned initiation in 2017 Multiple product candidates in late-stage clinical development illustrates transformational growth potential of Incyte's portfolio.
  • "Revenue growth from Jakafi and Iclusig continues to be very robust, driven by strong demand, and they bask in besides made significant progress across their clinical portfolio. As they spy forward to the second half of 2017, they anticipate the publication of essential data from their development candidates, as well as the initiation of multiple additional pivotal combination studies with epacadostat."
  • 7:10 am Innophos Holdings beats by $0.04, beats on revs; guides Q3 revs below two analyst estimate; reaffirms FY17 EPS guidance, revs guidance (IPHS) :

  • Reports Q2 (Jun) earnings of $0.57 per share, excluding non-recurring items, $0.04 better than the two analyst assay of $0.53; revenues fell 1.5% year/year to $179.14 mln vs the $172.65 mln two analyst estimate.
  • All segments showed positive year-over-year volume comparisons
  • Delivered final $2 million of $16 million procurement savings pipeline from side 1 Operational Excellence initiatives
  • H2 2017 on track to realize $5 million of the identified $13 million side 2 Operational Excellence cost savings in the areas of MRO, packaging and logistics
  • The acquisition of Novel Ingredients will create a Food, Health and Nutrition (FHN) platform of nearly $0.5 billion in revenue representing 60% of total sales. The combined Company will profit from leading, innovative technology; a broader and deeper product portfolio; and access to unique market segments
  • Co issues downside guidance for Q3, sees Q3 revs of down ~4% y/y to ~$178.59 mln vs. $186.30 mln two analyst estimate.
  • Earnings in the third quarter are forecast to be positively affected sequentially by reduced implementation fees and first-time cost savings from side 2 operational excellence.
  • Input costs are otherwise expected to be in line with second quarter 2017.
  • The Company anticipates that the tax rate will be at the more normalized level of approximately 33% in the thirdquarter.
  • Co reaffirms guidance for FY17, sees EPS of broadly in line with 2016 which was $2.55 vs. $2.48 two analyst estimate; sees FY17 revs of ~$696 mln vs. $692.45 mln Capital IQ Consensus Estimate.
  • On a full-year basis, overall market conditions and the competitive landscape for 2017 are expected to be similar to 2016.
  • The Company anticipates that the side 2 Operational Excellence fees incurred in the first half of the year will be more than offset by the side 2 savings, of which $5 million is estimated to rob outcome in the second half of 2017.
  • As a result of these factors, the Company continues to hope full-year revenues to be down by approximately 4% compared with 2016 (equates to ~$696 mln). The Company further continues to hope full-year earnings to be broadly in line with 2016, reflecting the impact of management's focus on cost actions and productivity initiatives given the challenging market conditions.
  • "We delivered a very robust second quarter with top and bottom line results above their expectations," said Kim Ann Mink, Ph.D., Chairman, President and Chief Executive Officer. "By remaining focused on cost savings from performance improvement initiatives, they grew margins on a year-over-year basis despite continuing market pressure. As they transition into the second half of the year, they are encouraged by several recent developments, including improvements in sales volume. They are confident in their capacity to deliver on a strong second half of the year and are reiterating their guidance, excluding the Novel Ingredients acquisition.
  • 7:09 am Schneider National reports EPS in-line, revs in-line; raises low-end of FY17 EPS guidance (SNDR) :

  • Reports Q2 (Jun) earnings of $0.23 per share, excluding non-recurring items, in-line with the Capital IQ Consensus of $0.23; revenues rose 8.1% year/year to $1.08 bln vs the $1.07 bln Capital IQ Consensus.
  • Co raises guidance for FY17, sees EPS of $0.94-1.02 (Prior $0.92-1.02) , excluding non-recurring items, vs. $0.97 Capital IQ Consensus Estimate.
  • "The market pressures of the first quarter continued into the second quarter," said Lofgren. "However, in June indications of improving market conditions began to appear. July is always a challenging month, so they will bask in a better read by mid-August, but they are cautiously optimistic that the market will see strengthening in the second half of 2017. The market improvement, their efforts to expand driver capacity, unique Dedicated contracts and their ongoing revenue management work positions us well for the second half of 2017. final quarter, I discussed my commitment to be thoughtful and disciplined as to capital expenditures. In light of anticipated market improvement and unique customer wins, they bask in increased their anticipated replete year net capital expenditures range to $350 million to $400 million which includes $100 million for chassis. Further, they anticipate replete year 2017 adjusted diluted earnings per share in the range of $0.94 to $1.02, which includes the impact of increased share count from the IPO estimated at $0.10 per share."
  • 7:08 am Phillips 66 beats by $0.08 (PSX) :

  • Reports Q2 (Jun) earnings of $1.09 per share, $0.08 better than the Capital IQ Consensus of $1.01.
  • Phillips 66 generated $1.9 billion in cash from operations during the second quarter, including $422 million of cash distributions from equity affiliates. Excluding working capital impacts, operating cash stream was $1.2 billion.
  • During the quarter, Phillips 66 funded $458 million of capital expenditures and investments, and distributed $360 million in dividends and $381 million in share repurchases. The company ended the quarter with 512 million shares outstanding.
  • As of June 30, 2017, cash and cash equivalents were $2.2 billion, and consolidated debt was $10.0 billion, including $2.3 billion at Phillips 66 Partners (PSXP). The company's consolidated debt-to-capital ratio and net-debt-to-capital ratio were 30 percent and 25 percent, respectively. Excluding PSXP, the debt-to-capital ratio was 26 percent and net-debt-to-capital ratio was 20 percent.
  • 7:07 am Dorman Products misses by $0.02, beats on revs (DORM) :

  • Reports Q2 (Jun) earnings of $0.83 per share, $0.02 worse than the Capital IQ Consensus of $0.85; revenues rose 9.4% year/year to $229.26 mln vs the $225.91 mln Capital IQ Consensus.
  • "In the quarter, they besides started to realize meaningful revenue from the launch of their Dorman Premium replete line chassis program. They are truly excited to see the results of a lot of hard work by the team as they strive to become a market leader in this category. Overall, they continue to execute well, and although they are very pleased with their first half growth, they remain cautious entering the back half of the year given current market conditions. However, their previously issued replete year guidance for top and bottom line growth remains unchanged" said Matt Barton, President and Chief Executive Officer.
  • Operating Cash stream was $3.8 million in the quarter compared to $12.6 million in the very quarter final year. Investment in inventories (of approximately $29 million in the quarter), to ensure towering customer fill rates, was the driver of the decreased Operating Cash Flows. They hope inventory to plateau in the third quarter and initiate to decline slightly in the second half of the year.
  • 7:05 am Innophos Holdings to acquire Novel Ingredients for $125 mln in cash (IPHS) :

    Novel Ingredients are a unique Jersey-based provider of dietary supplement ingredient solutions primarily owned by GenNx360 Capital Partners, a unique York-based private equity firm.

  • Under the terms of the merger agreement, Innophos will acquire replete of the outstanding shares of Novel Ingredients for a total purchase cost of $125 million (enterprise value), payable in cash.
  • Co will fund the acquisition with borrowings under its existing credit facility.
  • The acquisition is expected to be accretive to Innophos' earnings per share in the first year following the immediate of the transaction.
  • Closing of the transaction is expected to be completed in the third quarter of 2017.
  • Annual revenue of nearly $100 million; 2008-2016 CAGR of 19%.
  • Annual cost synergies estimated at $4 million; revenue synergies are anticipated from combined product technology and customer relationships
  • 7:05 am Shopify beats by $0.06, beats on revs; guides Q3 revs above consensus; raises FY17 above consensus; CFO will retire (SHOP) :

  • Reports Q2 (Jun) adj. loss of $0.01 per share, $0.06 better than the Capital IQ Consensus of ($0.07); revenues rose 75.2% year/year to $151.7 mln vs the $143.94 mln Capital IQ Consensus. Within this, Subscription Solutions revenue grew 64% to $71.6 million. The acceleration in Subscription Solutions revenue growth was driven by the continued rapid growth in Monthly Recurring Revenue as another record number of merchants joined the platform in the period. Merchant Solutions revenue grew 86% to $80.1 million, driven primarily by the growth of flagrant Merchandise Volume.MRR as of June 30, 2017 was $23.7 million, up 64% compared with $14.4 million as of June 30, 2016. Shopify Plus contributed $4.3 million, or 18%, of MRR compared with 13% of MRR as of June 30, 2016.GMV for the second quarter was $5.8 billion, an expand of $2.5 billion, or 74% over the second quarter of 2016. flagrant Payments Volume3 ("GPV") grew to $2.2 billion, which accounted for 38% of GMV processed in the quarter, versus $1.3 billion, or 38%, for the second quarter of 2016.Gross profit dollars grew 83% to $86.8 million as compared with the $47.5 million recorded for the second quarter of 2016.
  • Co issues upside guidance for Q3, sees Q3 revs of $164-166 mln vs. $157.03 mln Capital IQ Consensus Estimate; adj. operating loss $2-4 mln
  • Co issues upside guidance for FY17, sees FY17 revs of $642-648 mln vs. $627.77 mln Capital IQ Consensus Estimate; adj. operating loss $7-11 mln
  • Shopify's Chief pecuniary Officer Russ Jones has informed the Company and its Board of Directors of his determination to retire in 2018. Russ, who joined Shopify in 2011, intends to continue to serve as CFO until his successor is establish and has transitioned into the role, a process that is now underway and that Shopify expects will be completed within the next 12 months.
  • 7:05 am Archer-Daniels beats by $0.05, misses on revs (ADM) :

  • Reports Q2 (Jun) earnings of $0.57 per share, excluding non-recurring items, $0.05 better than the Capital IQ Consensus of $0.52; revenues fell 4.4% year/year to $14.94 bln vs the $15.86 bln Capital IQ Consensus.
  • "Our actions in the first half of the year reflect ADM's continuous efforts to create shareholder value. They are diversifying their capabilities and geographic gain through acquisitions and organic expansions. They are aggressively managing costs and capital, and taking additional portfolio actions; and they are ahead of pace to meet their 2017 target of $225 million in run-rate savings...With these collective actions, they hope to deliver solid year-over-year earnings growth and returns in 2017, and they are poised to be an even stronger company in 2018."
  • 7:03 am CME Group beats by $0.01, reports revs in-line (CME) :

  • Reports Q2 (Jun) earnings of $1.22 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of $1.21; revenues rose 2.1% year/year to $925 mln vs the $931.05 mln Capital IQ Consensus.
  • Second-quarter 2017 average daily volume was a record 16.5 million contracts, up 9 percent compared with second-quarter 2016.
  • Clearing and transaction fee revenue was $792 million, up 3 percent compared with second-quarter 2016.
  • Second-quarter 2017 total average rate per contract was 74.9 cents, up 2 percent from first-quarter 2017, driven primarily by a sequential product merge shift with an increased harmony of the volume from commodity contracts, which capture higher fees.
  • Market data revenue was $96 million, down 7 percent compared with the second quarter final year, but relatively in line with the first quarter of this year.
  • 7:03 am Steven Madden beats by $0.06, beats on revs; raises FY17 EPS, revs guidance (SHOO) :

  • Reports Q2 (Jun) earnings of $0.51 per share, excluding non-recurring items, $0.06 better than the Capital IQ Consensus of $0.45; revenues rose 15.0% year/year to $374.15 mln vs the $355.22 mln Capital IQ Consensus.
  • Gross margin was 37.3%. Adjusted flagrant margin was 37.4% as compared to 37.2% in the very age final year, an expand of 20 basis points.
  • Same store sales increased 2.2% in the quarter compared to a 5.4% very store sales expand in the second quarter of 2016. Retail flagrant margin decreased slightly to 62.6% in the second quarter of 2017 as compared to 62.8% in the second quarter of the prior year.
  • Co raises guidance for FY17, sees EPS of $2.18-2.24 (Prior $2.12-2.18), excluding non-recurring items, vs. $2.19 Capital IQ Consensus Estimate; sees FY17 revs of $1.53-1.55 bln (+9-11%) (Prior +8-10%) vs. $1.53 bln Capital IQ Consensus Estimate.
  • 7:03 am AcelRx reported key results from the side 3 IAP312 study of ZALVISO (sufentanil sublingual tablet system), an investigational product candidate being developed for the management of moderate-to-severe acute throe (ACRX) :

    Throughout the study in 320 enrolled patients, 2.2% of patients experienced a ZALVISO device error, which was statistically less than the 5% confine specified in the study objectives.

  • Importantly, no one of these device errors resulted in an over-dosing event.
  • This 2.2% rate was lower than the 7.9% rate of device errors during patient exhaust previously reported for the earlier version of the ZALVISO device in the side 3 IAP311 study.
  • In addition, as requested by FDA, the IAP312 study prospectively evaluated the number of inadvertently misplaced tablets which occurred during patient dosing.
  • No patient had a repeat incidence of an inadvertently misplaced tablet followingre-training on the device.
  • 7:03 am Pitney Bowes misses by $0.03, reports revs in-line; guides FY17 EPS in-line (PBI) :

  • Reports Q2 (Jun) earnings of $0.33 per share, excluding non-recurring items, $0.03 worse than the Capital IQ Consensus of $0.36; revenues fell 1.7% year/year to $821.4 mln vs the $822.9 mln Capital IQ Consensus.
  • Co issues narrows guidance for FY17, sees EPS of $1.70-1.78 from $1.70-1.85 vs. $1.74 Capital IQ Consensus Estimate.
  • Revenue, on a constant currency basis, to be in the range of flat to 1 percent growth, when compared to 2016. This has been updated from the original range of a 2 percent decline to 1 percent growth. Free cash stream to be in the range of $400 million to $430 million. This has been updated from the original range of $400 million to $460 million.
  • 7:03 am Caterpillar CFO Brad Halverson to retire in early 2018; co will launch an external search to fill the position (CAT) :  

    7:02 am Under Armour beats by $0.03, beats on revs; lowers FY17 guidance; announces restructuring (UAA) :

  • Reports Q2 (Jun) loss of $0.03 per share, excluding non-recurring items, $0.03 better than the Capital IQ Consensus of ($0.06); revenues rose 8.7% year/year to $1.09 bln vs the $1.08 bln Capital IQ Consensus, up 8 percent currency neutral. Revenue to wholesale customers rose 3 percent to $655 million and direct-to-consumer revenue was up 20 percent to $386 million. A dynamic and promotional retail environment in North America continued to temper results with revenue in line with final year's very period. Outside North America, the strong momentum continued with international revenue up 57 percent (up 54 percent currency neutral), representing 22 percent of total revenue. Within their international business, revenue in EMEA was up 57 percent (up 53 percent currency neutral), up 89 percent in Asia-Pacific (up 87 percent currency neutral) and up 10 percent in Latin America (up 9 percent currency neutral). Apparel revenue increased 11 percent to $681 million including strength in men's and women's training, and golf. Footwear revenue was down 2 percent to $237 million, against final year's very age which was up 58 percent due to significant strength in basketball sales. Accessories revenue increased 22 percent to $123 million with strength in men's and women's training, and youth performance.
  • Gross margin declined 190 basis points to 45.8 percent as benefits from channel and product merge were offset by inventory management initiatives, changes in alien currency rates, and higher air freight in connection with their enterprise resource planning (:ERP) system implementation, which impacted the timing of shipments to inevitable key customers.
  • Co issues guidance for FY17, sees EPS of $0.37-0.40, excluding non-recurring items, vs. $0.42 Capital IQ Consensus Estimate; sees FY17 revs of +9-11% to ~$5.26-5.36 bln vs. $5.35 bln Capital IQ Consensus Estimate. 
  • Under Armour's Board of Directors has approved a restructuring design to more closely align its pecuniary resources to support the company's efforts to better serve the evolving needs of the changing consumer and customer landscape. "As they stand up their category management structure within a consumer-led approach, they intend to meaningfully expand their go-to-market speed and amplify their digital capabilities," continued Plank. "We've identified a number of areas to enhance their operational capabilities, drive process improvement and gain greater efficiencies. They remain steadfast in driving and building their brand while shifting their operational focus to become more return-on-investment and cost of capital centric - institutionalizing discipline to deliver more consistent, long-term shareholder value." In conjunction with this plan, the company expects to incur total estimated pre-tax restructuring and related charges of ~$110-130 million. 
  • 7:01 am Cara Therapeutics appoints Mani Mohindru, Ph.D., as CFO efficacious August 15 (CARA) :

  • Josef Schoell, who has held the CFO position at Cara for more than a decade, will be retiring.
  • Most recently, Mohindru served as Chief Strategy Officer at Curis (CRIS)
  • 7:01 am Granite Constr misses by $0.20, beats on revs (GVA) :

  • Reports Q2 (Jun) earnings of $0.35 per share, excluding non-recurring items, $0.20 worse than the Capital IQ Consensus of $0.55; revenues rose 26.2% year/year to $762.9 mln vs the $684.32 mln Capital IQ Consensus.
  • The Company's expectations for 2017 are:
  • Mid- to high-teens consolidated revenue growth
  • Consolidated EBITDA margin1 of 6.0% to 6.5%
  • "Our businesses continue to win unique work across the portfolio, with broad project wins driving Company backlog above $4 billion for the first time in their Company's 95-year history. For the fifth consecutive quarter, Construction segment backlog finished above the $1-billion mark"
  • 7:00 am Xylem beats by $0.02, reports revs in-line; guides FY17 EPS above consensus, revs above consensus (XYL) :

  • Reports Q2 (Jun) earnings of $0.59 per share, excluding non-recurring items, $0.02 better than the Capital IQ Consensus of $0.57; revenues rose 24.9% year/year to $1.16 bln vs the $1.17 bln Capital IQ Consensus.
  • Co issues raised guidance for FY17, sees EPS of $2.30-2.40 from $2.23-2.38, excluding non-recurring items, vs. $2.31 Capital IQ Consensus Estimate; raises FY17 revs of $4.65-4.70 bln from $4.50-4.60 bln vs. $4.6 bln Capital IQ Consensus Estimate.
  • Orders exceeded $1.2 billion in the second quarter, growing eight percent organically. On a pro forma organic basis, Xylem projects revenue growth of three to four percent. On an organic basis, which excludes the impact of acquisitions and the impact of alien exchange translation, Xylem's revenue growth is now anticipated to be in the range of two to three percent. "Looking ahead, they bask in solid plans and are operating in improving conclude markets, which reinforce their confidence in their capacity to deliver solid growth and margin expansion in line with their improved guidance for the replete year."
  • 7:00 am Bristol-Myers announces that the FDA has approved Opdivo (nivolumab) injection for the treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed with a fluoropyrimidine, oxaliplatin, and irinotecan (BMY) :

    Approval for this indication has been granted under accelerated approval based on overall response rate (:ORR) and duration of response.

  • In the CheckMate -142 trial, among patients who received prior treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, 28% responded to treatment with Opdivo.
  • Among these responders, the median duration of response was not reached
  • Opdivo is associated with the following Warnings and Precautions including immune-mediated: pneumonitis, colitis, hepatitis, endocrinopathies, nephritis and renal dysfunction, skin adverse reactions, encephalitis, other adverse reactions; infusion reactions; and embryo-fetal toxicity.
  • 7:00 am Asian Markets Close: Nikkei +0.3%, Hang Seng +0.8%, Shanghai +0.6% (:SUMRX) :

    Equity indices in the Asia-Pacific region ended Tuesday on a higher note. Regional economic data included below-consensus Manufacturing PMI readings from India and Japan while China's Caixin Manufacturing PMI beat expectations. The People's Bank of China reportedly uncovered operational violations at 40 Chinese banks. The banks bask in up to six months to rectify the issues. In Japan, Chief Cabinet Secretary Yoshihide Suga confirmed that Prime Minister Shinzo Abe plans to reshuffle his cabinet on August 3. The Reserve Bank of Australia left its cash rate unchanged at 1.50%, as expected. The central bank notable that the relative strength of the Australian dollar results from weakness in the U.S. dollar. The Reserve Bank of India will meet overnight.

  • In economic data:
  • Japan's July Manufacturing PMI 52.1 (expected 52.2; final 52.2)
  • China's July Caixin Manufacturing PMI 51.1 (consensus 50.4; final 50.4)
  • India's Nikkei July Manufacturing PMI 47.9 (expected 50.8; final 50.9)
  • South Korea's July Nikkei Manufacturing PMI 49.1 (last 50.1)
  • Australia's July AIG Manufacturing Index 56.0 (last 55.0)
  • South Korea's July CPI +0.2% month-over-month (last -0.1%); +1.9% year-over-year (consensus 2.0%; final 1.9%). July trade surplus narrowed to KRW10.65 billion from KRW10.77 billion. July Imports +14.5% year-over-year (last 19.8%) and July Exports +19.5% year-over-year (last 13.6%)
  • ---Equity Markets---

  • Japan's Nikkei edged up 0.3%. Toshiba spiked 11.0% while Nitto Denko, Yamato Holdings, Teijin, Sumitomo Mitsui Financial, T&D Holdings, Dentsu, Sumitomo Mitsui, Sony pecuniary Holdings, and Mitsubishi advanced between 1.8% and 3.7%.
  • Hong Kong's Hang Seng climbed 0.8%, nearing its towering from 2015. Financials ended in the lead with Ping An Insurance, China Life Insurance, BoC Hong Kong, Bank of China, Bank of East Asia, China Construction Bank, ICBC, and Hang Seng Bank climbed between 0.8% and 4.1%. On the downside, Geely Automobile lost 1.8%.
  • China's Shanghai Composite slipped from its towering in afternoon action, but charged to a fresh towering into the close, adding 0.6%. Shanghai Jin Jiang International Industrial Investment, Shanghai Lujiazui Finance & Trade Zone Development, Anhui Expressway, Bestsun Energy, and Beijing Teamsun Technology gained between 4.5% and 5.1%.
  • India's Sensex ticked up 0.2% with more than half of its components touching higher. Hero MotoCorp, Maruti Suzuki, and Mahidra&Mahindra gained between 1.8% and 2.1% while tech consultants were mixed. Wipro gained 1.8%, Tata Consultancy shed 0.2%, and Infosys lost 0.6%. Lupin was the weakest performer, falling 1.4%.
  • ---FX---

  • USDJPY +0.2% to 110.45
  • USDCNY -0.1% to 6.7203
  • USDINR -0.1% to 64.08
  • 6:57 am Glatfelter Co misses by $0.13, misses on revs (GLT) :

  • Reports Q2 (Jun) loss of $0.06 per share, excluding non-recurring items, $0.13 worse than the Capital IQ Consensus of $0.07; revenues fell 4.7% year/year to $387.3 mln vs the $394.84 mln Capital IQ Consensus.
  • In the Composite Fibers and Advanced Airlaid Materials industry units, net sales increased by 1.4% and 4.9%, respectively, on a constant currency basis.
  • Specialty Papers' net sales declined 8.6% in the quarter-over-quarter comparison.
  • "We had solid growth in shipping volumes and improved performance in their engineered materials businesses during the quarter," said Dante C. Parrini, Chairman and Chief Executive Officer. "However, their overall results for the quarter were lower than expected due to continued weakness in Specialty Papers' markets. Volumes in their Composite Fibers industry strengthened, increasing 3% over final year's second quarter and 4% year-to-date, driven by improved claim across most product lines and particularly wall cover products. While they are seeing steady growth in the Composite Fibers business, they remain focused on their cost optimization initiatives that are expected to deliver $10 million in cost savings in 2017. The Advanced Airlaid Materials industry performed well delivering top-line growth and improved profitability, as operating income increased 11% over the prior-year quarter and 10% for the year. For the remnant of 2017, they hope continued growth in shipments and strong operating performance from their engineered materials businesses. They besides spy forward to the incremental growth expected from their unique Fort Smith, Arkansas facility coming on-line later this year with commercial shipments dawn early 2018."
  • 6:56 am Louisiana-Pacific reports EPS in-line, revs in-line (LPX) :

  • Reports Q2 (Jun) earnings of $0.58 per share, excluding non-recurring items, in-line with the Capital IQ Consensus of $0.58; revenues rose 19.2% year/year to $694 mln vs the $700.73 mln Capital IQ Consensus. 
  • "Despite concerns about lot availability and labor shortages constraining unique construction, they are encouraged by the year-over-year expand in single-family starts...In the second half of the year, they will remain focused on sustainable improvements and growth in replete of their businesses, including continued siding growth and launching of unique specialty products."
  • 6:54 am Mosaic beats by $0.06, reports revs in-line (MOS) :

  • Reports Q2 (Jun) earnings of $0.29 per share, excluding $0.01 in non-recurring items, $0.06 better than the Capital IQ Consensus of $0.23; revenues rose 4.7% year/year to $1.75 bln vs the $1.75 bln Capital IQ Consensus.
  • Guidance: Total sales volumes for the Phosphates segment are expected to range from 2.2 to 2.5 mln tonnes for the third quarter of 2017, compared to 2.5 mln tonnes final year. Total sales volumes for the Potash segment are expected to range from 1.9 to 2.2 mln tonnes for the third quarter of 2017, compared to 2.2 mln tonnes final year. For calendar 2017, Mosaic now expects: Canadian resource taxes to range from $90 to $110 mln, narrowed from previous guidance of $85 to $135 mln. Brine management costs to range from $150 to $160 mln, down from $160 to $180 mln. Capital expenditures in the range of $800 to $850 mln down from a range of $800 to $900 mln. Potash sales volumes in the range of 8.1 to 8.6 mln tonnes, narrowed from 8.0 to 8.75 mln tonnes. Phosphates sales volumes in the range of 9.5 to 10 mln tonnes, narrowed from 9.5 to 10.25 mln tonnes. International Distribution sales volumes in the range of 6.75 to 7.25 mln tonnes, down from 7.0 to 7.5 mln tonnes.
  • 6:51 am Xerox beats by $0.07, misses on revs; narrows FY17 EPS in-line (XRX) :

  • Reports Q2 (Jun) earnings of $0.87 per share, excluding non-recurring items, $0.07 better than the Capital IQ Consensus of $0.80; revenues fell 8.1% year/year to $2.57 bln vs the $2.6 bln Capital IQ Consensus.
  • Co issues in-line guidance for FY17, sees EPS of $3.20-3.44 (prior: $3.2-3.52) vs. $3.34 Capital IQ Consensus Estimate.
  • Xerox continues to hope to generate operating cash stream from continuing operations of $700 to $900 million and free cash stream from continuing operations of $525 to $725 million in 2017.
  • "We are pleased with the strong operating margins and cash stream they delivered, as well as the continued progress on their Strategic Transformation initiatives," said Jeff Jacobson, Xerox chief executive officer. "This resulted in solid operating results despite revenue declines, which were driven by lower outfit sales as they transition to the recently launched ConnectKey portfolio." Jacobson added, "The unique product line-up has been met with enthusiasm by customers, partners and industry experts, fueling their confidence in improving revenue trends later this year and into next."
  • 6:51 am Intl Game Tech. PLC misses by $0.17, beats on revs; reaffirms EBITDA guidance (IGT) :

  • Reports Q2 (Jun) earnings of $0.15 per share, excluding non-recurring items, $0.17 worse than the Capital IQ Consensus of $0.32; revenues fell 5.1% year/year to $1.22 bln vs the $1.2 bln Capital IQ Consensus. The constant currency decline of 5% is mostly attributable to the unique Lotto concession dynamics and the sale of Double Down Interactive LLC, which closed on June 1, 2017. Global lottery same-store revenue, excluding Italy, grew 2.6% in the second quarter, on top of strong North America jackpot activity in the prior year period. Excluding multi-state jackpot games, global lottery same-store revenue grew 4.9%. In Italy, late numbers activity was lower than the elevated levels in the second quarter of 2016. Excluding late numbers, Italy Lotto wagers increased 1%. Gaming service revenue was primarily impacted by the sale of DoubleDown. The global installed foundation continues to grow, rising 2,701 units from the prior-year period. Global gaming product revenue increased 5% over the second quarter of 2016 driven by 25% growth in terminal sales that was partially offset by lower systems sales. The Company shipped 8,884 gaming machines worldwide during the second quarter, led by strong replacement unit demand.
  • The Company is maintaining its outlook for adjusted EBITDA of $1,600-$1,680 million, and the expectation for net debt remains $6,950-$7,150 million for the replete year 2017 period. The outlook for maintenance and growth capital expenditures has been reduced by $50 million to $575-$625 million.
  • 6:51 am TransUnion prices 22.5 mln (upsized from 20 mln shares) common stock offering by selling stockholders; cost not disclosed (TRU) :  

    6:50 am CONSOL Energy beats by $0.07, beats on revs; updates guidance (CNX) :

  • Reports Q2 (Jun) earnings of $0.17 per share, $0.07 better than the Capital IQ Consensus of $0.10; revenues rose 202.8% year/year to $865.95 mln vs the $678.79 mln Capital IQ Consensus.
  • During the second quarter of 2017, CONSOL's E&P Division sold 92.2 Bcfe, or a reduce of 7% from the 99.3 Bcfe sold in the year-earlier quarter, which resulted primarily from both timing delays associated with the TIL schedule and from the company selling approximately 3.0 Bcfe of production related to the net developed acres located in Doddridge and Wetzel counties, West Virginia. As stated final quarter, the company expected to TIL three pads in the second quarter; however, due to operational delays, the company ended up turning-in-line one pad. Therefore, the company expects to TIL five pads in the third quarter, which includes the two delayed pads from the second quarter. Lastly, the reduce of 3.0 Bcfe of production associated with the West Virginia sale was retroactive starting on January 1, 2017 through May 31, 2017.
  • Guidance: 
  • CONSOL Energy maintains its E&P Division production guidance for 2017 of approximately 420-440 Bcfe, while increasing its total E&P capital expenditures in 2017 to approximately $620-$645 million, compared to previous guidance of approximately $555 million. The expand in 2017 capital is driven primarily by three areas: additional capital associated with operational challenges in the second quarter, service cost inflation related to pressure pumping services, and continuous improvement progress. The continuous improvement progress is driven by improved drilling cycle times resulting in the company expecting to drill nine additional wells in 2017 and by modifying production protocols, both of which are expected to expand 2018 production to 520-550 Bcfe, compared to previous guidance of 490-520 Bcfe. Also, the company has added another layer of hedges for the expected incremental production in 2018 to lighten lock in returns and cash flows.
  • 6:47 am Extended Stay America reports EPS in-line, misses on revs; lowers FY17 revs guidance (STAY) :

  • Reports Q2 (Jun) earnings of $0.31 per share, in-line with the Capital IQ Consensus of $0.31; revenues rose 1.7% year/year to $338.36 mln vs the $342.7 mln Capital IQ Consensus.
  • Comparable Hotel RevPAR for the three months ended June 30, 2017 grew 2.4% over the very age in 2016, driven by an improvement in occupancy of 220 basis points to 78.9% while average Daily Rate ("ADR") declined slightly by 0.5%. Comparable Hotel RevPAR for the six months ended June 30, 2017 grew 2.3% to $49.44 driven by a 150 basis point expand in occupancy and a 0.2% expand in ADR compared to the very age in 2016.
  • Co lowers guidance for FY17, sees FY17 revs of $1.278-1.303 bln (Prior $1.285-1.31 bln) vs. $1.3 bln Capital IQ Consensus Estimate; continues to see comparable RevPAR +1.5-3.5%
  • 6:47 am Houston American Energy provides production information on its Johnson State #1H well and provided an update with respect to the status of its drilling and completion operations in Reeves County, Texas (HUSA) :

    On July 28, 2017, the operator on the Johnson State well began the process of shutting in the well pending completion of production handling facilities and tying into the gas sales line, which is anticipated within the next two weeks.

  • Prior to shut in, the latest daily flowback report indicated production rates of 351 barrels of oil per day and 4,269 mcf of natural gas per day, or a combined 1,062 barrels of oil equivalent per day. 
  • The company's second Reeves County well, the O'Brien #3H, reached total depth on July 1, 2017.
  • The well, with a 4,575 foot horizontal leg in the Upper Wolfcamp A shale, is scheduled to commence hydraulic fracturing operations during the second half of August 2017. 
  • We hope to see meaningful improvements in their production, revenue and profitability by the conclude of Q3 2017."
  • 6:47 am Pfizer beats by $0.01, misses on revs; raises low conclude of FY17 EPS, reaffirms FY17 revs guidance (PFE) :

  • Reports Q2 (Jun) earnings of $0.67 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of $0.66; revenues fell 1.9% year/year to $12.9 bln vs the $13.08 bln Capital IQ Consensus. reflecting a slight operational decline of $48 million and the unfavorable impact of alien exchange of $202 million, or 2%. Excluding the revenues for HIS in both periods and the unfavorable impact of alien exchange, second-quarter 2017 revenues increased by $248 million, or 2%. Second-quarter 2017 revenues excluding the net impact of acquisitions and divestitures completed in 2016 and the first six months of 2017 were flat operationally compared to second-quarter 2016.
  • Co issues guidance for FY17, raises EPS to $2.54-2.60 from $2.50-2.60, excluding non-recurring items, vs. $2.55 Capital IQ Consensus Estimate; reaffirms FY17 revs of $52-54 bln vs. $52.78 bln Capital IQ Consensus Estimate.
  • 6:47 am Waddell & Reed beats by $0.01, reports revs in-line (WDR) :

  • Reports Q2 (Jun) earnings of $0.39 per share, excluding non-recurring items, $0.01 better than the Capital IQ Consensus of $0.38; revenues fell 10.2% year/year to $286.7 mln vs the $285.25 mln Capital IQ Consensus.
  • The second quarter of 2017 excluded a tax permeate of $8.9 million ($0.11 per diluted share) related to the implementation of unique accounting guidance regarding the tax consequences of share-based payments. Assets under management ended the second quarter of 2017 at $80.4 billion, decreasing less than 1% compared to the prior quarter and decreasing 7% compared to the second quarter of 2016.
  • 6:44 am Tata Motors domestic sales grows by 13% in July 2017 (TTM) :

  • The overall commercial vehicles sales in July 2017, in the domestic market were at 27,842 nos. higher by 15% over July 2016, due to ramp-up of BS4 production, across segments. The Company besides passed on the benefits of GST to consumers by reducing the prices of its vehicles across replete commercial vehicle segments.
  • In July 2017, Tata Motors passenger vehicles, in the domestic market, recorded sales at 14,933 nos., with a growth of 10%, over 13,547 units, in July 2016, due to continued strong claim for the Tata Tiago and the Tata Tigor. While the car segment marginally degrew by 1% at 12,125 nos., the UV segment grew by 110% at 2,808 nos., due to strong claim for Tata HEXA.
  • 6:44 am Kamada reports EPS in-line, misses on revs; reaffirms FY17 revs guidance (KMDA) :

  • Reports Q2 (Jun) earnings of $0.13 per share, in-line with the Capital IQ Consensus of $0.13; revenues rose 70.7% year/year to $32.55 mln vs the $33.3 mln two analyst estimate.
  • Co reaffirms guidance for FY17, sees FY17 revs of $100 mln vs. $101.31 mln two analyst estimate.
  • Upcoming Milestones:
  • PDUFA date of August 29, 2017 for the completion of the review of the BLA for Anti-Rabies IgG therapy.
  • Expect to receive FDA approval to conduct a pivotal side 3 trial for inhaled AAT.
  • Last patient enrolled in February 2017 in the Company's Type-1 Diabetes side 2 trial; top-line results anticipated in the second half of 2017.
  • Completed patient recruitment in the Company's lung transplantation side 2 trial; hope to bask in an interim report from this trial in the second half of 2017.
  • Anticipate submitting Clinical Trial Application for IV AAT in GvHD in Europe in the second half of 2017, and initiating the combined U.S. and European trial in 2018.
  • As of June 30, 2017, the Company had cash, cash equivalents and short term investments of $26.9 million, compared with $28.6 million as of December 31, 2016.
  • 6:41 am Mobile Mini appoints Van Welch to Executive Vice President & CFO, efficacious August 31, 2017 (MINI) : Most recently, Mr. Welch held the position of Executive Vice President and Chief pecuniary Officer at Willbros Inc. (WG), and previously served in senior finance roles at KBR Group.

    6:41 am WestJet reports Q2 results (WJAFF) :

  • Co reported Q2 EPS of CAD 0.41 vs CAD 0.30 final year; revs +11.1% YoY to CAD 1.055 bln.
  • WestJet achieved its 49th consecutive quarter of profitability and flew a record 5.9 million guests. Based on the trailing twelve months, the airline achieved a return on invested capital of 9.8 per cent, compared with the 10.0 per cent reported in the previous quarter.
  • 6:41 am Edge Therapeutics reports Q2 net loss, in-line (EDGE) :

  • Q2 EPS ($0.44) vs ($0.44) Capital IQ Consensus Estimate
  • "NEWTON 2, their side 3 clinical study designed to support potential registrations throughout the world for EG-1962 as a treatment for aneurysmal subarachnoid hemorrhage (aSAH) delivered via external ventricular drain, is ongoing. They spy forward to the study's pre-planned futility analysis in late-2017, top-line efficacy results from the interim analysis in the first quarter of 2018 and, if needed, top-line results from the replete study in late-2018. They are besides evaluating alternative routes of administration to expand the population of aSAH patients who may profit from EG-1962. This includes their ongoing controlled study of EG-1962 delivered directly into the basal cisterns of the brain in good-grade patients with ruptured brain aneurysms. In addition, during the quarter, they initiated development activities for lumbar administration of EG-1962. There remains a significant unmet necessity to ameliorate outcomes in patients with aSAH, and they spy forward to receiving EG-1962 data in the coming quarters."
  • 6:40 am property Systems beats by $0.02, beats on revs; lowers FY18 EPS in-line, reaffirms FY18 revs guidance (QSII) :

  • Reports Q1 (Jun) earnings of $0.17 per share, excluding non-recurring items, $0.02 better than the Capital IQ Consensus of $0.15; revenues rose 7.1% year/year to $130.9 mln vs the $126.75 mln Capital IQ Consensus.
  • Co issues guidance for FY18, sees EPS of $0.62-0.70 (prior: $0.66-0.74), excluding non-recurring items, vs. $0.70 Capital IQ Consensus Estimate; sees FY18 revs of $512-530 mln vs. $521.93 mln Capital IQ Consensus Estimate.
  • Lowering FY18 EPS guidance to account for incremental investments in the EagleDream Health platform. 
  • "Fiscal 2018 is off to a very solid start, as they saw strong pecuniary results and continued to do progress on their strategic plan. During the quarter, they leveraged their platform as a service strategy to further enhance their solution offerings and enhance the value they bring to their clients. Furthermore, the significant modifications we've made to their industry model will simplify the process and expand the ease of partnering with NextGen going forward. I feel very confident in their position within the market and their capacity to drive bookings growth in the back half of fiscal 2018," commented Rusty Frantz, President and Chief Executive Officer of property Systems, Inc.
  • 6:38 am Horizon Global beats by $0.17, beats on revs; guides Q3 EPS below consensus, revs above consensus; raises FY17 EPS above consensus, reaffirms FY17 revs guidance; acquires Best Bars Ltd. (HZN) :

  • Reports Q2 (Jun) adj. earnings of $0.84 per share, $0.17 better than the Capital IQ Consensus of $0.67; revenues rose 51.1% year/year to $253.6 mln vs the $241.08 mln Capital IQ Consensus.
  • Co issues mixed guidance for Q3, sees EPS of $0.35-0.40, excluding non-recurring items, vs. $0.44 Capital IQ Consensus Estimate; sees Q3 revs of $225-235 mln vs. $220.78 mln Capital IQ Consensus Estimate.
  • Co issues guidance for FY17, raises EPS to $1.04-1.14, excluding non-recurring items, vs. $0.98 Capital IQ Consensus Estimate; reaffirms FY17 rev +30-35%.
  • Regionally, Horizon Americas delivered strong growth in e-commerce and aftermarket channels as sales recovered from order delays in the first quarter of 2017. Horizon Asia-Pacific experienced double-digit organic growth by expanding into industrial products. As a whole, the Company's operating profit more than doubled as a result of leverage from increased sales and operational improvements." "We reiterate their confidence in achieving 9 million in expected synergies during 2017 due to their Westfalia integration efforts. The momentum in Horizon Europe-Africa continues to build, and they hope to realize ongoing benefits from the industry in the back half of 2017 and beyond.
  • "We are besides pleased to promulgate their recently completed acquisition of Best Bars Limited, an established leader in the towing and trailering industry in unique Zealand. Best Bars is now Part of Horizon Asia-Pacific, and they hope this acquisition to support the growth of their global OE business."
  • 6:38 am Eaton misses by $0.01, reports revs in-line; guides Q3 EPS in-line; narrows FY17 EPS in-line (ETN) :

  • Reports Q2 (Jun) earnings of $1.15 per share, $0.01 worse than the Capital IQ Consensus of $1.16; revenues rose 1.0% year/year to $5.13 bln vs the $5.14 bln Capital IQ Consensus.
  • Co issues in-line guidance for Q3, sees EPS of $1.20-1.30 vs. $1.28 Capital IQ Consensus Estimate.
  • Co issues narrows guidance for FY17, sees EPS of $4.50-4.70 from $4.45-4.75 vs. $4.65 Capital IQ Consensus Estimate.
  • "Operating margins in the second quarter were 17.5 percent, and excluding restructuring costs of $11 million, 18.1 percent...Margins increased 0.5 percentage point over the first quarter of 2017, excluding restructuring costs in both quarters."
  • 6:36 am Versum Materials beats by $0.08, beats on revs; raises FY17 guidance (VSM) :

  • Reports Q3 (Jun) earnings of $0.52 per share, excluding non-recurring items, $0.08 better than the Capital IQ Consensus of $0.44; revenues rose 19.8% year/year to $290.8 mln vs the $265.64 mln Capital IQ Consensus.
  • Adjusted EBITDA for the fiscal third quarter ended June 30, 2017 was $97.7 million versus $80.3 million in the very quarter a year ago, a 21.7% expand year on year. Strong volumes in both DS&S and Materials coupled with modestly favorable currency were partially offset by expected higher operating and selling and administrative costs associated with becoming an independent company and unfavorable price/mix in the Materials segment, primarily in Process Materials.
  • Co raises guidance for FY17, sees FY17 revs of $1.09-1.12 bln (Prior $1.02-1.065 bln) vs. $1.07 bln Capital IQ Consensus Estimate; sees Adj-EBITDA of $365-375 mln (Prior $340-355 mln)
  • 6:36 am Denison Mining reports a unique high-grade uranium intersection in basement rocks from the first pocket completed as Part of the summer 2017 drilling program at the Waterbury Lake property (DNN) :

    Drill pocket WAT-17-443 intersected 1.1% eU3O8 over 0.8 metres (from 296.9 to 297.7 metres) ~1.5 kilometres to the northeast of the property's J Zone uranium deposit.

  • The high-grade mineralization occurs immediately below a broader 10.3 metre mineralized interval (from 282.8 to 293.1 metres) with an average grade of 0.15% eU3O8.
  • The mineralization is open in replete directions and follow-up drilling is presently underway.
  • 6:36 am Ingredion beats by $0.03, misses on revs; reaffirms FY17 EPS guidance (INGR) :

  • Reports Q2 (Jun) earnings of $1.89 per share, $0.03 better than the Capital IQ Consensus of $1.86; revenues rose 0.1% year/year to $1.46 bln vs the $1.5 bln Capital IQ Consensus.
  • Co reaffirms guidance for FY17, sees EPS of $7.50-7.80, excluding non-recurring items, vs. $7.58 Capital IQ Consensus Estimate.
  • "We continue to deliver shareholder value with another strong quarter, including solid operating income and earnings per share growth. genuine operating efficiency, the impact of acquisitions, and higher specialty volumes more than offset headwinds in South America," said Ilene Gordon, chairman, president and chief executive officer. "Operating income in North America reached record levels, but was lower in South America due to macroeconomic headwinds and the temporary interruption of manufacturing activities in Argentina associated with the implementation of a unique labor agreement."
  • 6:35 am Harris reports EPS in-line, beats on revs; guides FY18 EPS below consensus, revs in-line (HRS) :

  • Reports Q4 (Jun) earnings of $1.49 per share, excluding non-recurring items, in-line with the Capital IQ Consensus of $1.49; revenues rose 0.6% year/year to $1.54 bln vs the $1.52 bln Capital IQ Consensus.
  • Co issues guidance for FY18, sees EPS of $5.85-6.05, excluding non-recurring items, vs. $6.08 Capital IQ Consensus Estimate; sees FY18 revs of $6.02-6.14 bln vs. $6.07 bln Capital IQ Consensus Estimate. Harris expects fiscal 2018 free cash stream in a range of $850 - 900 million.
  • "Our fiscal 2017 performance, including higher revenue and strong orders in the fourth quarter, positions us well for returning to growth in fiscal 2018 and accelerating in the medium term...We enter the year at an inflection point, with positive momentum and a continued focus on generating organic growth, driving flawless execution, maintaining margins through operational excellence, and deploying capital in a balanced manner."
  • 6:34 am Epizyme and US Oncology Research promulgate a collaboration to screen and identify relapsed or refractory follicular lymphoma and diffuse big B-cell lymphoma patients with EZH2 mutations (EPZM) :

    Under the collaboration, US Oncology Research will implement a separate screening protocol in 68 locations in the U.S. to identify relapsed or refractory FL and DLBCL patients with tumors presence EZH2 mutations who may be candidates for enrollment in Epizyme's ongoing side 2 clinical trial.

  • US Oncology Research will direct identified patients to the tazemetostat side 2 clinical trial for protocol screening and potential enrollment into the trial. Sites began screening patients in July 2017.
  • 6:34 am Crestwood Equity Partners reports Q2 (Jun) results, beats on revs; updates outlook (CEQP) :

  • Reports Q2 (Jun) loss of $0.28 per share, may not be comparable to the Capital IQ Consensus of ($0.07); revenues rose 41.3% year/year to $850.3 mln vs the $706.34 mln Capital IQ Consensus.
  • Second quarter 2017 Adjusted EBITDA of $97.3 million, compared to $106.5 million in the second quarter 2016; Adjusted EBITDA for the second quarter 2017 reflects the deconsolidation of Stagecoach Gas Services compared to the second quarter 2016 which included 100% contribution in April and May 2016
  • Updated Outlook:
  • Adjusted EBITDA of $380 million to $400 million
  • Distributable cash stream of $210 million to $230 million
  • Growth project capital spending and joint venture contributions unchanged in the range of $225 million to $250 million
  • 6:33 am property Systems to acquire EagleDream Health, a cloud-based analytics company, for $26 mln in cash (QSII) :

    With its vendor-agnostic platform for managing value-based care, EagleDream Health empowers organizations with intuitive analytics and actionable intelligence to achieve successful population health management.

  • The proposed acquisition will enable NextGen Healthcare to enhance the permeate taste and expand patient engagement for ambulatory clinics and health systems while reducing the per capita cost of healthcare and improving the work-life poise for clinicians and staff.
  • The transaction is expected to immediate in the current quarter.
  • 6:33 am Thomson Reuters beats by $0.09, reports revs in-line; raises FY17 EPS above consensus; reaffirms revenue (TRI) :

  • Reports Q2 (Jun) earnings of $0.60 per share, excluding non-recurring items, $0.09 better than the Capital IQ Consensus of $0.51; revenues rose 0.5% year/year to $2.78 bln vs the $2.78 bln Capital IQ Consensus, recurring revenues and contributions from acquisitions were mostly offset by the impact of alien currency. At constant currency, revenues increased 2%. Operating profit was essentially unchanged as slightly higher revenues and lower expenses, which reflected savings from the company's simplification initiatives, were offset by the unfavorable impact of impartial value adjustments associated with alien currency derivatives embedded in inevitable customer contracts.
  • Co issues guidance for FY17, raises EPS to $2.40-2.45 from $2.35, excluding non-recurring items, vs. $2.35 Capital IQ Consensus Estimate. Based on the results of the first half of the year, the company raised its full-year outlook for adjusted EBITDA margin and adjusted EPS. The company reaffirmed its full-year outlook for revenue growth and free cash flow. For the full-year 2017, the company currently expects: Low single-digit revenue growth Adjusted EBITDA margin to range between 29.3% - 30.3% - up from previous guidance of 28.8% - 29.8% Free cash stream to range between $0.9 billion and $1.2 billion, which reflects cash payments in 2017 relating to the fourth-quarter 2016 charges, the $500. 
  • 6:33 am Willbros Group CFO Van A. Welch to resign after accepting a similar position in a different industry efficacious August 30 (WG) :  

    6:32 am Radian Group beats by $0.07, beats on revs (RDN) :

  • Reports Q2 (Jun) earnings of $0.48 per share, excluding non-recurring items, $0.07 better than the Capital IQ Consensus of $0.41; revenues rose 4.9% year/year to $302.91 mln vs the $299.07 mln Capital IQ Consensus.
  • New MI industry written increases 11% and MI in coerce increases 8% year-over-year.
  • Book value per share grows 3% and tangible reserve value per share grows 12% year-over-year.
  • "I am pleased to report on their strong operating performance in the second quarter, including a 26% expand in adjusted diluted net operating income per share, 8% growth in their mortgage insurance in coerce and a 12% expand in tangible reserve value per share," said Radian's Chief Executive Officer Rick Thornberry. "I continue to be excited about the opportunities ahead for Radian. They bask in a unique chance to leverage their market-leading Mortgage Insurance franchise combined with their core capabilities across the Services segment to deliver high-value and relevant products and services. Successfully capturing these opportunities will enable us to further deepen customer relationships, grow sustainable revenues and profitability and expand stockholder value."
  • 6:32 am Glowpoint completes debt recapitalization, resulting in an expand of approx. $8.7 mln to stockholders' equity; therefore, the co expects to meet the continued listing standards of the NYSE (GLOW) :  

    6:32 am Columbus McKinnon beats by $0.19, beats on revs (CMCO) :

  • Reports Q1 (Jun) earnings of $0.51 per share, $0.19 better than the Capital IQ Consensus of $0.32; revenues rose 36.7% year/year to $203.7 mln vs the $190.62 mln Capital IQ Consensus.
  • Backlog increased 12.2% to $173.3 million as of June 30, 2017 compared with March 31, 2017.
  • "We anticipate that sales in the fiscal second quarter will be comparable with the quarter just completed, although sales merge will provide a bit lower operating income. In the meantime, they remain focused on their near-term priorities: the integration of STAHL, strengthening their core industry for greater profitability, further leveraging their Magnetek technology for greater revenue potential and reducing debt."
  • 6:31 am Holly Energy Partners misses by $0.10, misses on revs (HEP) :

  • Reports Q2 (Jun) earnings of $0.36 per share, $0.10 worse than the two analyst assay of $0.46; revenues rose 15.0% year/year to $109.14 mln vs the $113.12 mln Capital IQ Consensus.
  • Distributable cash stream was $60.9 million for the quarter, up $5.2 million, or 9.3% compared to the second quarter of 2016. HEP announced its 51stconsecutive distribution expand on July 27, 2017, raising the quarterly distribution from $0.62 to $0.6325 per unit, which represents an expand of 8.1% over the distribution for the second quarter of 2016, exceeding HEP's distribution growth target of 8%.
  • 6:27 am WestRock acquires Hannapak a provider of folding cartons to a variety of markets, including beverage, food, confectionary, and healthcare; WestRock will pay AUD$75 mln in cash (WRK) :  

    6:22 am Corvel reports Q1 results (CRVL) :

  • Q1 EPS $0.46 vs. $0.38 final year; rev +7% to $138 mln (no estimates).
  • Revenue growth for the quarter was driven by an expand in the Company's claims management services. Network Solutions, including Pharmacy profit Management (PBM) programs, besides had improved results driven by CorVel's value-added performance for clients. Payors face increasing pressure to lighten accommodate inflating medical costs which has increased interest in the Company's medical review and provider management services. The Company recently announced the release of an advanced claims management workstation for the insurance carrier marketplace.
  • 6:18 am ICHOR Corporation commences public offering of 5.5 mln ordinary shares by selling shareholders (ICHR) :  

    6:18 am Freeport-McMoRan sells inevitable interest in the Gulf of Mexico Outer Continental Shelf to Cox Oil Offshore; terms not disclosed (FCX) :  

    6:13 am On The Wires (:WIRES) :

  • Visa (V) announced its support of the unique global QR Code Payment Specifications from EMVCo, the global technical cadaver that manages the EMV Specifications. The specifications cover consumer-presented and merchant-presented QR code exhaust cases for digital payment acceptance. QR codes are two-dimensional machine-readable barcodes, used to facilitate mobile payments at the point-of-sale.
  • Cellcom Israel Ltd. (CEL) announced that following the previously reported amendment to the Company's cellular license in relation to the requirement that Israeli citizens and residents from among the Company's founding shareholders hold at least 5% of the Company's outstanding shares and other means of control, as of July 2017, the Israeli Ministry of Communications amended the Company's cellular license so as to postpone the application of such requirement until October 31, 2017.
  • TransAlta Corporation (TAC) and TransAlta Renewables responded to Fortescue Metals Group Limited's (FSUMF) view that the South Hedland Power Station has not yet achieved commercial operation. replete the conditions to establishing that commercial operations bask in been achieved under the terms of the power purchase agreement with FMG bask in been satisfied in full. These conditions comprehend receiving a commercial operation certificate, successfully completing and passing inevitable test requirements, and obtaining replete permits and approvals required from the North West Interconnected System and government agencies. The South Hedland Power Station is fully operational and able to meet replete of FMG's requirements under the terms of the PPA.
  • 6:11 am MDC Holdings beats by $0.03, beats on revs (MDC) :

  • Reports Q2 (Jun) earnings of $0.64 per share, $0.03 better than the Capital IQ Consensus of $0.61; revenues rose 13.6% year/year to $648.97 mln vs the $623.95 mln Capital IQ Consensus.
  • Selling, common and administrative expenses as a percentage of home sale revenues improved 40 basis points from 11.3% to 10.9%.
  • Dollar value of net unique orders of $710.6 million versus $722.5 million.
  • Monthly sales absorption pace of 3.41 improved 2%.
  • Ending backlog dollar value up 4% to $1.68 billion from $1.61 billion.
  • Approved 3,342 lots for purchase in 44 communities.
  • Last twelve months return on equity improved 340 basis points to 9.3%.
  • Larry A. Mizel, MDC's Chairman and Chief Executive Officer, stated, "We are pleased to promulgate their 2017 second quarter results, highlighted by a 26% year-over-year expand in their net income. For the second consecutive quarter, they realized a year-over-year improvement in their backlog conversion rate, which helped to drive a double-digit expand in home sale revenues and improved operating leverage. The improved backlog conversion rate was achieved based on stabilizing build-to-order construction cycle times, which decreased sequentially for the first time in almost two years."
  • 6:10 am Pioneer Energy misses by $0.02, beats on revs; offers Q3 guidance (PES) :

  • Reports Q2 (Jun) loss of $0.21 per share, excluding non-recurring items, $0.02 worse than the Capital IQ Consensus of ($0.19); revenues rose 72.0% year/year to $107.13 mln vs the $105.23 mln Capital IQ Consensus.
  • Q3 Outlook:
  • In the third quarter of 2017, Production Services Segment revenue is estimated to be up approximately 5% to 10% as compared to the second quarter of 2017. Production Services Segment margin is estimated to be 24% to 26% of revenues in the third quarter. Drilling rig utilization in the third quarter is estimated to average 74% to 77%. Drilling Services Segment margin is expected to be approximately $8,100 to $8,500 per day in the third quarter.
  • 6:09 am Archrock beats by $0.12, beats on revs (AROC) :

  • Reports Q2 (Jun) loss of $0.03 per share, excluding non-recurring items, $0.12 better than the Capital IQ Consensus of ($0.15); revenues rose 4.2% year/year to $198 mln vs the $196 mln two analyst estimate. 
  • "During the quarter, they grew operating horsepower by 40,000 horsepower, improved contract operations flagrant margin percentage by 200 basis points, and increased EBITDA, as adjusted, $7 million sequentially. They continued to drive unique orders at impressive levels, and in spite of the recent commodity cost pull-back, claim for their services has remained at elevated levels providing visibility of unique starts through 2017 and into 2018." "As they bask in communicated over the past nine months, 2017 is a transition year with the prior cyclical downturn giving way to the expansion they expected in the second half of 2017," continued Childers.
  • "We are confident that expansion is underway and they hope to see solid year-over-year growth in year-end 2017 operating horsepower and replete year aftermarket services revenue."
  • 6:08 am Baytex Energy Trust reports Q2 (Jun) results, beats on revs; updates guidance (BTE) :

  • Reports Q2 (Jun) earnings of CC$0.04 per share, may not be comparable to the Capital IQ Consensus of (CC$0.19); revenues rose 40.2% year/year to CC$274.37 mln vs the CC$259.23 mln single analyst estimate.
  • Production increased 5% to average 72,812 boe/d (79% oil and NGL) in Q2/2017, as compared to 69,298 boe/d (79% oil and NGL) in Q1/2017. Production in the first half of 2017 averaged 71,065 boe/d. During the second quarter, exploration and development capital expenditures totaled $78.0 million, bringing the aggregate spending in the first half of 2017 to $174.6 million. They participated in the drilling of 47 (15.3 net) wells with a 100% success rate during the second quarter.
  • Updated guidance:
  • Reflective of their strong operating results in the first half of the year, they are tightening their 2017 production guidance range to 69,000 to 70,000 boe/d (previously 68,000 to 70,000 boe/d). They are now forecasting full-year 2017 exploration and development capital expenditures of $310 to $330 million (previously $325 to $350 million). They are besides reducing their guidance for operating expenses by 4% (at the mid-point) to $10.75-$11.25/boe as they continue to drive cost efficiencies in their business.
  • 6:08 am Archrock Partners beats by $0.01, reports revs in-line (APLP) :

  • Reports Q2 (Jun) earnings of $0.08 per share, $0.01 better than the Capital IQ Consensus of $0.07; revenues fell 1.3% year/year to $138.3 mln vs the $137.1 mln Capital IQ Consensus. 
  • EBITDA, as adjusted was $66.9 million for the second quarter of 2017, compared to $61.1 million for the first quarter of 2017 and $71.2 million for the second quarter of 2016.
  • 6:06 am Sequans Communications reports EPS in-line, misses on revs; guides Q3 EPS below consensus, revs below consensus (SQNS) :

  • Reports Q2 (Jun) loss of $0.06 per share, excluding non-recurring items, in-line with the Capital IQ Consensus of ($0.06); revenues rose 33.8% year/year to $13.22 mln vs the $14.48 mln Capital IQ Consensus.
  • Gross margin was 42.1% compared to 47.1% in the first quarter of 2017 and compared to 44.6% in the second quarter of 2016, reflecting an expand in the harmony of module sales in the product merge in the second quarter of 2017.
  • Co issues downside guidance for Q3, sees EPS of ($0.07-0.05), excluding non-recurring items, vs. ($0.04) Capital IQ Consensus Estimate; sees Q3 revs of $15-17 mln vs. $17.59 mln Capital IQ Consensus Estimate.
  • 6:06 am Air Products beats by $0.06, beats on revs; guides Q4 EPS in-line (APD) :

  • Reports Q3 (Jun) earnings of $1.65 per share, excluding non-recurring items, $0.06 better than the Capital IQ Consensus of $1.59; revenues rose 10.8% year/year to $2.12 bln vs the $2.06 bln Capital IQ Consensus on eight percent higher volumes and five percent favorable energy pass-through, partially offset by two percent unfavorable currency. Volumes were positive across replete three regions, while continued progress on the Jazan project was partially offset by lower LNG activity. Taken together, the Industrial Gas regions increased overall volumes by eight percent. Pricing was flat with the prior year.
  • Co issues in-line guidance for Q4, sees EPS of $1.65-1.70, excluding non-recurring items, vs. $1.67 Capital IQ Consensus Estimate.
  • Co issues in-line guidance for FY17, raises EPS $0.10 to $6.20-6.25, excluding non-recurring items, vs. $6.15 Capital IQ Consensus Estimate. 
  • "We continue to be optimistic about the future performance of Air Products. They see significant opportunities to exhaust their very strong poise sheet to invest in their core industry and create value for their shareholders. They bask in increased their full-year guidance by $0.10 at midpoint, now representing a 10 percent expand over prior year." 
  • 6:06 am Lumber Liquidators beats by $0.24, beats on revs; comparable store sales +8.8% (LL) :

  • Reports Q2 (Jun) earnings of $0.16 per share, $0.24 better than the Capital IQ Consensus of ($0.08); revenues rose 10.7% year/year to $263.5 mln vs the $256.89 mln Capital IQ Consensus.
  • Net sales in comparable stores increased $21 million, or 8.8%, driven by a 5.3% expand in the number of customers invoiced and a 3.5% expand in the average sale.
  • Merchandise sales in comparable stores grew 6.1% in the quarter. Net sales in non-comparable stores increased $4.4 million.
  • The Company did not open any stores during the second quarter of 2017, so total store count remained at 385 as of June 30, 2017.
  • Dennis Knowles, Chief Executive Officer, commented, "In the quarter, they saw positive results in net revenues, comparable store sales and customer traffic, in addition to flagrant margin expansion which drove positive operating results. Customers bask in responded to the investments that they made to broaden and strengthen their assortment with innovative products, while besides ensuring the perquisite merge of those products were available in their stores. Although they are pleased with the results in the quarter, they still bask in work to do. Their management team is confident in the potential of their business, and remains dedicated to carrying out the long-term strategy of the Company. They believe that by continuing to work their plan, they will position the Company for long-term profitability and growth."
  • 6:05 am Genesee & Wyoming beats by $0.07, reports revs in-line (GWR) :

  • Reports Q2 (Jun) earnings of $0.80 per share, excluding non-recurring items, $0.07 better than the Capital IQ Consensus of $0.73; revenues rose 7.8% year/year to $540.43 mln vs the $539.59 mln Capital IQ Consensus.
  • North American Operations traffic increased 10,924 carloads, or 2.8%, to 397,047 carloads in the second quarter of 2017. Excluding 11,483 carloads from unique operations, very railroad traffic decreased 559 carloads, or 0.1%. The traffic reduce was principally due to decreases of 1,873 carloads of metallic ores traffic (primarily in the Mountain West and Coastal regions), 1,839 carloads of petroleum products traffic (primarily in the Northeast and Mountain West regions), 1,695 carloads of metals traffic (primarily in the Southern and Coastal regions), 1,547 carloads of chemicals and plastics traffic (primarily in the Mountain West Region) and 1,514 carloads of pulp and paper traffic (primarily in the Southern and Coastal regions), partially offset by increases of 3,235 carloads of agricultural products traffic (primarily in the Central and Mountain West regions), 2,422 carloads of waste traffic (primarily in the Northeast and Pacific regions) and 1,380 carloads of minerals and stone traffic (primarily in the Central Region). replete remaining traffic increased by a net 872 carloads.
  • 6:03 am Gener8 Maritime misses by $0.05, misses on revs (GNRT) :

  • Reports Q2 (Jun) loss of $0.11 per share, excluding non-recurring items, $0.05 worse than the Capital IQ Consensus of ($0.06); revenues fell 29.3% year/year to $74.95 mln vs the $76.55 mln two analyst estimate.
  • Increased vessel operating days by 18.0% to 3,352 in the three months ended June 30, 2017 compared to 2,841 in the very age in the prior year. Increased replete fleet "ECO" operating days to 54.2% in the three months ended June 30, 2017, compared to 30.8% in the very age in the prior year.
  • "We continue to rob essential steps to strengthen their platform and poise sheet" said Peter Georgiopoulos, Chairman and Chief Executive Officer of Gener8 Maritime. "In this seasonally weaker rate environment, they remain focused on maximizing their pecuniary flexibility in order to manage their industry for the near- and long-term. They continue to dispose of older vessels, streamlining their fleet and focusing on towering property tonnage with the best return profile. This strengthens their competitive position in the market. They believe the strategy they are pursuing is prudent and reflects their approach to managing their poise sheet and market exposure."
  • 6:03 am Armada Hoffler Properties reports FFO in-line, misses on revs; lowers FY17 FFO guidance (AHH) :

  • Reports Q2 (Jun) funds from operations of $0.25 per share, in-line with the Capital IQ Consensus of $0.25; revenues rose 10.4% year/year to $26.76 mln vs the $27.18 mln Capital IQ Consensus.
  • Co lowers guidance for FY17, sees FFO of $0.97-0.99 (Prior $0.99-1.03) vs. $0.98 Capital IQ Consensus Estimate.
  • 5:50 am Shanghai...+0.60% (FXI) :  

    5:50 am S&P futures vs impartial value: +8.50. Nasdaq futures vs impartial value: +32.60. :

    5:50 am European Markets : FTSE...7427.36...+55.40...+0.80%.  DAX...12166...+47.50...+0.40%.

    5:50 am Asian Markets : Nikkei...19986...+60.60...+0.30%.  Hang Seng...27540...+216.20...+0.80%.

    5:26 am Sony beats by JPY 6.53, beats on revs; raises FY18 revs outlook (SNE) :

  • Reports Q1 (Jun) earnings of YEN62.70 per share (Basic EPS was YEN64.03), YEN6.53 better than the Capital IQ Consensus of YEN56.17; revenues rose 15.2% year/year to YEN1858.1 bln vs the YEN1735.86 bln Capital IQ Consensus.
  • Co raises guidance for FY18, sees FY18 revs of YEN8300 bln (Prior YEN8000 bln) vs. YEN8021.31 bln Capital IQ Consensus Estimate.
  • 5:05 am Allot Comms reports EPS in-line, beats on revs; reaffirms FY17 revs guidance (ALLT) :

  • Reports Q2 (Jun) loss of $0.07 per share, excluding non-recurring items, in-line with the Capital IQ Consensus of ($0.07); revenues fell 15.1% year/year to $19.52 mln vs the $19.2 mln Capital IQ Consensus.
  • Co reaffirms guidance for FY17, sees FY17 revs of $80-84 mln vs. $81.58 mln Capital IQ Consensus Estimate. Revenues for the second half of 2017 are expected to be better than for the first half and the reserve to bill ratio for the year is expected to be above 1.
  • 4:34 am Mazor Robotics beats by $0.08, reports revs in-line (Pre-announced Q2 revs) (MZOR) :

  • Reports Q2 (Jun) loss of $0.05 per share, excluding non-recurring items, $0.08 better than the single analyst assay of ($0.13); revenues rose 86.7% year/year to $15.46 mln vs the $15.38 mln Capital IQ Consensus. The company pre-announced Q2 sales/orders in early July
  • The Company's flagrant margin for the three months ended June 30, 2017 was 69.4% compared to 76.9% in the year-ago second quarter. This expected reduce is attributed mainly to the higher manufacturing costs of the Mazor X compared to the Renaissance system and the inclusion of four Renaissance trade-ins to Mazor X
  • As previously announced, the Company received purchase orders for 19 systems in the 2017 second quarter and ended the quarter with a backlog of 14 systems.
  • 4:20 am On The Wires (:WIRES) :

  • Showa Denko (SHWDY) has decided to expand prices of its high-purity fluorine-based gases for electronics. Specifically, SDK will expand prices of high-purity FC-116 and FC-14 gases by about 500 yen (US$4.5) per kilogram each as from shipments on September 1, 2017. SDK will start contacting its customers concerning this cost increase. The company besides announced that it started to supply "low-carbon" hydrogen gas made from used plastics (low-carbon hydrogen) at its Kawasaki Plant to TOMOE SHOKAI Co., Ltd.'s Shinsuna Hydrogen Station located in Koto-ku, Tokyo final month.
  • Wirecard (WRCDF) and mobilcom-debitel announced a 'ground-breaking collaboration'. From today onwards, replete unique Android smartphones sold by mobilcom-debitel will Come with the preinstalled mobile payment app boon.
  • Isogenica Ltd, a leader in the design and construction of innovative and highly diverse synthetic antibody libraries, announced a unique licensing deal with Takeda Pharmaceutical Company Limited (TKPYY). Under the terms of the agreement, Isogenica has granted Takeda licences to its family of llamdA VHH single-domain antibody libraries for the discovery, development and commercialisation of therapeutic products derived from these libraries. Isogenica is entitled to an upfront and annual licence payments. If antibodies are advanced into development, Isogenica is entitled to further licence fees, milestones and royalties.
  • Morrisons (MRWSY) is pleased to promulgate a major new, long-term wholesale supply initiative with McColl's, which will rob wholesale supply sales to more than 1bn in due course. Morrisons is to start supplying both Safeway products and national brands to 1,300 McColl's convenience shops and 350 newsagents across the UK1. The unique partnership will supplant replete McColl's existing supply arrangements in time. Morrisons will supply McColl's shops, with a phased programme starting in January 2018. By the conclude of 2018, the co expects total annualised wholesale sales to replete its partners to be in excess of 700m (inc. tobacco). The co expects this unique initiative to do an initial profit contribution in 2018/19, and expand thereafter.
  • Anglo American plc (NGLOY) announces the value of rough diamond sales (Global Sightholder Sales and Auction Sales) for De Beers' sixth sales cycle of 2017, amounting to $572 million.
  • 4:19 am AstraZeneca granted Breakthrough Therapy Designation by the FDA for acalabrutinib for the treatment of patients with mantle cell lymphoma who bask in received at least one prior therapy (AZN) : The Breakthrough Therapy Designation is designed to expedite the development and regulatory review of unique medicines that are intended to treat a serious condition and that bask in shown encouraging early clinical results, which demonstrate substantial improvement on a clinically-significant endpoint over available medicines and when there is significant unmet medical need.

    4:08 am British American Tobacco says the Serious Fraud Office has opened a formal investigation into allegations of misconduct (BTI) : "As previously announced, they are investigating, through external legal advisers, allegations of misconduct. They bask in been co-operating with the Serious Fraud Office ("SFO") and British American Tobacco ("BAT") has been informed that the SFO has now opened a formal investigation. BAT intends to co-operate with that investigation."

    3:58 am Worldpay & Vantiv (VNTV) granted extension by Panel on Takeovers and Mergers to finalize terms of their potential merger (WDDYF) :

    For reference, on 5 July 2017, Worldpay and Vantiv (VNTV) announced that they had reached agreement in principle on the key terms of a potential merger of Worldpay and Vantiv. The announcement stated that in accordance with Rule 2.6(a) of the UK Takeover Code, Vantiv is required to clarify its intentions by no later than 5.00pm on 1 August 2017 (the "PUSU Deadline"), by either announcing a hard intent to do an proffer or that it does not intend to do an offer.

  • Positive discussions are continuing between Worldpay and Vantiv, but there can be no certitude that a hard proffer will be forthcoming.
  • Therefore, the Board of Worldpay has requested that the Panel on Takeovers and Mergers (the "Panel") extend the PUSU Deadline. In the light of this request, an extension has been granted by the Panel and, in accordance with Rule 2.6(a) of the Code, Vantiv is required, by not later than 5.00pm on 8 August 2017, either to promulgate a hard intent to do an proffer in accordance with Rule 2.7 of the Code or to promulgate that it does not intend to do an offer, in which case the announcement will be treated as a statement to which Rule 2.8 of the Code applies.
  • 3:17 am On The Wires (:WIRES) :

  • Graa y Montero S.A.A. (GRAM) announced it signed an agreement with five banks to provide a $162.1 million credit line to GyM, the construction company of the Group, and an additional line of $100 million in order to develop future projects of the company.
  • R1 RCM Inc. (RCM) announced that Central Maine Healthcare, an integrated healthcare delivery system serving 400,000 people animate in central, western, and mid-coast Maine, selected R1 for its Revenue Capture Solutions module.
  • CTI BioPharma Corp. (CTIC) announced that the first patient has been enrolled in PAC203, a side 2 clinical trial of pacritinib in patients with primary myelofibrosis who bask in failed prior ruxolitinib therapy. PAC203 is designed to evaluate the dose response relationship for safety and efficacy (spleen volume reduction at 12 and 24 weeks) of three dose regimens: 100 mg once-daily, 100 mg twice-daily (BID) and 200 mg BID. The 200 mg BID dose regimen was used in the side 3 PERSIST-2 trial of pacritinib in patients with myelofibrosis. The trial is expected to enroll up to approximately 105 patients.
  • Hiab, Part of Cargotec (CYJBF), has entered into an agreement to acquire the loader crane industry of one of Brazil's leading loader crane manufacturers Argos Guindastes Indstria e Comrcio Ltda. The acquisition is expected to rob Place during the third quarter 2017. The parties bask in agreed not to disclose the transaction value.
  • LivaNova PLC (LIVN) announced its latest VNS Therapy Systems received CE notice for expanded MRI labeling. VNS Therapy is now the only implantable device indicated for epilepsy therapy that allows patients to bask in high-quality 1.5T and 3T MRI scans without the necessity for special equipment.
  • 3:15 am common Motors closes sale of Opel/Vauxhall industry to the Groupe PSA (PEUGF) (GM) : The sale of GM Financial's European operations to Groupe PSA and BNP Paribas (BNPQY) is expected to immediate later this year, subject to various regulatory approvals.

    3:05 am Bank of Marin to acquire Bank of Napa (OTC: BNNP) for $51 mln in stock (BMRC) :

    Bank of Napa has two offshoot offices serving Napa County, and had assets of $246.1 million, total deposits of $217.7 million, and total loans of $139.3 million as of June 30, 2017.

  • The transaction will be immediately accretive to BMRC's earnings, adding to shareholder value. BNNP shareholders will receive a fixed exchange ratio of 0.3070 shares of BMRC common stock for each share of BNNP common stock outstanding. Based on BMRC's closing stock cost of $65.95 on July 28, 2017, the transaction is valued at $51.0 million, or $20.25 per share of BNNP common stock. Such value will fluctuate with changes in the stock cost of BMRC. The total transaction value includes the value of BNNP options assumed by BMRC.
  • The transaction is expected to immediate in the fourth quarter of 2017, and upon closing the Bank will bask in approximately $2.4 billion in assets and operate twenty-two branches in five counties, including San Francisco, Marin, Sonoma, Napa and Alameda.


  • Direct Download of over 5500 Certification Exams

    3COM [8 Certification Exam(s) ]
    AccessData [1 Certification Exam(s) ]
    ACFE [1 Certification Exam(s) ]
    ACI [3 Certification Exam(s) ]
    Acme-Packet [1 Certification Exam(s) ]
    ACSM [4 Certification Exam(s) ]
    ACT [1 Certification Exam(s) ]
    Admission-Tests [13 Certification Exam(s) ]
    ADOBE [93 Certification Exam(s) ]
    AFP [1 Certification Exam(s) ]
    AICPA [2 Certification Exam(s) ]
    AIIM [1 Certification Exam(s) ]
    Alcatel-Lucent [13 Certification Exam(s) ]
    Alfresco [1 Certification Exam(s) ]
    Altiris [3 Certification Exam(s) ]
    Amazon [2 Certification Exam(s) ]
    American-College [2 Certification Exam(s) ]
    Android [4 Certification Exam(s) ]
    APA [1 Certification Exam(s) ]
    APC [2 Certification Exam(s) ]
    APICS [2 Certification Exam(s) ]
    Apple [69 Certification Exam(s) ]
    AppSense [1 Certification Exam(s) ]
    APTUSC [1 Certification Exam(s) ]
    Arizona-Education [1 Certification Exam(s) ]
    ARM [1 Certification Exam(s) ]
    Aruba [6 Certification Exam(s) ]
    ASIS [2 Certification Exam(s) ]
    ASQ [3 Certification Exam(s) ]
    ASTQB [8 Certification Exam(s) ]
    Autodesk [2 Certification Exam(s) ]
    Avaya [96 Certification Exam(s) ]
    AXELOS [1 Certification Exam(s) ]
    Axis [1 Certification Exam(s) ]
    Banking [1 Certification Exam(s) ]
    BEA [5 Certification Exam(s) ]
    BICSI [2 Certification Exam(s) ]
    BlackBerry [17 Certification Exam(s) ]
    BlueCoat [2 Certification Exam(s) ]
    Brocade [4 Certification Exam(s) ]
    Business-Objects [11 Certification Exam(s) ]
    Business-Tests [4 Certification Exam(s) ]
    CA-Technologies [21 Certification Exam(s) ]
    Certification-Board [10 Certification Exam(s) ]
    Certiport [3 Certification Exam(s) ]
    CheckPoint [41 Certification Exam(s) ]
    CIDQ [1 Certification Exam(s) ]
    CIPS [4 Certification Exam(s) ]
    Cisco [318 Certification Exam(s) ]
    Citrix [47 Certification Exam(s) ]
    CIW [18 Certification Exam(s) ]
    Cloudera [10 Certification Exam(s) ]
    Cognos [19 Certification Exam(s) ]
    College-Board [2 Certification Exam(s) ]
    CompTIA [76 Certification Exam(s) ]
    ComputerAssociates [6 Certification Exam(s) ]
    Consultant [2 Certification Exam(s) ]
    Counselor [4 Certification Exam(s) ]
    CPP-Institue [2 Certification Exam(s) ]
    CPP-Institute [1 Certification Exam(s) ]
    CSP [1 Certification Exam(s) ]
    CWNA [1 Certification Exam(s) ]
    CWNP [13 Certification Exam(s) ]
    Dassault [2 Certification Exam(s) ]
    DELL [9 Certification Exam(s) ]
    DMI [1 Certification Exam(s) ]
    DRI [1 Certification Exam(s) ]
    ECCouncil [21 Certification Exam(s) ]
    ECDL [1 Certification Exam(s) ]
    EMC [129 Certification Exam(s) ]
    Enterasys [13 Certification Exam(s) ]
    Ericsson [5 Certification Exam(s) ]
    ESPA [1 Certification Exam(s) ]
    Esri [2 Certification Exam(s) ]
    ExamExpress [15 Certification Exam(s) ]
    Exin [40 Certification Exam(s) ]
    ExtremeNetworks [3 Certification Exam(s) ]
    F5-Networks [20 Certification Exam(s) ]
    FCTC [2 Certification Exam(s) ]
    Filemaker [9 Certification Exam(s) ]
    Financial [36 Certification Exam(s) ]
    Food [4 Certification Exam(s) ]
    Fortinet [12 Certification Exam(s) ]
    Foundry [6 Certification Exam(s) ]
    FSMTB [1 Certification Exam(s) ]
    Fujitsu [2 Certification Exam(s) ]
    GAQM [9 Certification Exam(s) ]
    Genesys [4 Certification Exam(s) ]
    GIAC [15 Certification Exam(s) ]
    Google [4 Certification Exam(s) ]
    GuidanceSoftware [2 Certification Exam(s) ]
    H3C [1 Certification Exam(s) ]
    HDI [9 Certification Exam(s) ]
    Healthcare [3 Certification Exam(s) ]
    HIPAA [2 Certification Exam(s) ]
    Hitachi [30 Certification Exam(s) ]
    Hortonworks [4 Certification Exam(s) ]
    Hospitality [2 Certification Exam(s) ]
    HP [746 Certification Exam(s) ]
    HR [4 Certification Exam(s) ]
    HRCI [1 Certification Exam(s) ]
    Huawei [21 Certification Exam(s) ]
    Hyperion [10 Certification Exam(s) ]
    IAAP [1 Certification Exam(s) ]
    IAHCSMM [1 Certification Exam(s) ]
    IBM [1530 Certification Exam(s) ]
    IBQH [1 Certification Exam(s) ]
    ICAI [1 Certification Exam(s) ]
    ICDL [6 Certification Exam(s) ]
    IEEE [1 Certification Exam(s) ]
    IELTS [1 Certification Exam(s) ]
    IFPUG [1 Certification Exam(s) ]
    IIA [3 Certification Exam(s) ]
    IIBA [2 Certification Exam(s) ]
    IISFA [1 Certification Exam(s) ]
    Intel [2 Certification Exam(s) ]
    IQN [1 Certification Exam(s) ]
    IRS [1 Certification Exam(s) ]
    ISA [1 Certification Exam(s) ]
    ISACA [4 Certification Exam(s) ]
    ISC2 [6 Certification Exam(s) ]
    ISEB [24 Certification Exam(s) ]
    Isilon [4 Certification Exam(s) ]
    ISM [6 Certification Exam(s) ]
    iSQI [7 Certification Exam(s) ]
    ITEC [1 Certification Exam(s) ]
    Juniper [63 Certification Exam(s) ]
    LEED [1 Certification Exam(s) ]
    Legato [5 Certification Exam(s) ]
    Liferay [1 Certification Exam(s) ]
    Logical-Operations [1 Certification Exam(s) ]
    Lotus [66 Certification Exam(s) ]
    LPI [24 Certification Exam(s) ]
    LSI [3 Certification Exam(s) ]
    Magento [3 Certification Exam(s) ]
    Maintenance [2 Certification Exam(s) ]
    McAfee [8 Certification Exam(s) ]
    McData [3 Certification Exam(s) ]
    Medical [69 Certification Exam(s) ]
    Microsoft [368 Certification Exam(s) ]
    Mile2 [2 Certification Exam(s) ]
    Military [1 Certification Exam(s) ]
    Misc [1 Certification Exam(s) ]
    Motorola [7 Certification Exam(s) ]
    mySQL [4 Certification Exam(s) ]
    NBSTSA [1 Certification Exam(s) ]
    NCEES [2 Certification Exam(s) ]
    NCIDQ [1 Certification Exam(s) ]
    NCLEX [2 Certification Exam(s) ]
    Network-General [12 Certification Exam(s) ]
    NetworkAppliance [36 Certification Exam(s) ]
    NI [1 Certification Exam(s) ]
    NIELIT [1 Certification Exam(s) ]
    Nokia [6 Certification Exam(s) ]
    Nortel [130 Certification Exam(s) ]
    Novell [37 Certification Exam(s) ]
    OMG [10 Certification Exam(s) ]
    Oracle [269 Certification Exam(s) ]
    P&C [2 Certification Exam(s) ]
    Palo-Alto [4 Certification Exam(s) ]
    PARCC [1 Certification Exam(s) ]
    PayPal [1 Certification Exam(s) ]
    Pegasystems [11 Certification Exam(s) ]
    PEOPLECERT [4 Certification Exam(s) ]
    PMI [15 Certification Exam(s) ]
    Polycom [2 Certification Exam(s) ]
    PostgreSQL-CE [1 Certification Exam(s) ]
    Prince2 [6 Certification Exam(s) ]
    PRMIA [1 Certification Exam(s) ]
    PsychCorp [1 Certification Exam(s) ]
    PTCB [2 Certification Exam(s) ]
    QAI [1 Certification Exam(s) ]
    QlikView [1 Certification Exam(s) ]
    Quality-Assurance [7 Certification Exam(s) ]
    RACC [1 Certification Exam(s) ]
    Real-Estate [1 Certification Exam(s) ]
    RedHat [8 Certification Exam(s) ]
    RES [5 Certification Exam(s) ]
    Riverbed [8 Certification Exam(s) ]
    RSA [15 Certification Exam(s) ]
    Sair [8 Certification Exam(s) ]
    Salesforce [5 Certification Exam(s) ]
    SANS [1 Certification Exam(s) ]
    SAP [98 Certification Exam(s) ]
    SASInstitute [15 Certification Exam(s) ]
    SAT [1 Certification Exam(s) ]
    SCO [10 Certification Exam(s) ]
    SCP [6 Certification Exam(s) ]
    SDI [3 Certification Exam(s) ]
    See-Beyond [1 Certification Exam(s) ]
    Siemens [1 Certification Exam(s) ]
    Snia [7 Certification Exam(s) ]
    SOA [15 Certification Exam(s) ]
    Social-Work-Board [4 Certification Exam(s) ]
    SpringSource [1 Certification Exam(s) ]
    SUN [63 Certification Exam(s) ]
    SUSE [1 Certification Exam(s) ]
    Sybase [17 Certification Exam(s) ]
    Symantec [134 Certification Exam(s) ]
    Teacher-Certification [4 Certification Exam(s) ]
    The-Open-Group [8 Certification Exam(s) ]
    TIA [3 Certification Exam(s) ]
    Tibco [18 Certification Exam(s) ]
    Trainers [3 Certification Exam(s) ]
    Trend [1 Certification Exam(s) ]
    TruSecure [1 Certification Exam(s) ]
    USMLE [1 Certification Exam(s) ]
    VCE [6 Certification Exam(s) ]
    Veeam [2 Certification Exam(s) ]
    Veritas [33 Certification Exam(s) ]
    Vmware [58 Certification Exam(s) ]
    Wonderlic [2 Certification Exam(s) ]
    Worldatwork [2 Certification Exam(s) ]
    XML-Master [3 Certification Exam(s) ]
    Zend [6 Certification Exam(s) ]





    References :


    Dropmark : http://killexams.dropmark.com/367904/11885797
    Wordpress : http://wp.me/p7SJ6L-1Y6
    Dropmark-Text : http://killexams.dropmark.com/367904/12857556
    Blogspot : http://killexamsbraindump.blogspot.com/2017/12/pass4sure-a00-281-dumps-and-practice.html
    RSS Feed : http://feeds.feedburner.com/WhereCanIGetHelpToPassA00-281Exam
    Box.net : https://app.box.com/s/2tkn3nide1zs4mkoumy4d8g2k9dhvscl






    Back to Main Page





    Killexams exams | Killexams certification | Pass4Sure questions and answers | Pass4sure | pass-guaratee | best test preparation | best training guides | examcollection | killexams | killexams review | killexams legit | kill example | kill example journalism | kill exams reviews | kill exam ripoff report | review | review quizlet | review login | review archives | review sheet | legitimate | legit | legitimacy | legitimation | legit check | legitimate program | legitimize | legitimate business | legitimate definition | legit site | legit online banking | legit website | legitimacy definition | pass 4 sure | pass for sure | p4s | pass4sure certification | pass4sure exam | IT certification | IT Exam | certification material provider | pass4sure login | pass4sure exams | pass4sure reviews | pass4sure aws | pass4sure security | pass4sure cisco | pass4sure coupon | pass4sure dumps | pass4sure cissp | pass4sure braindumps | pass4sure test | pass4sure torrent | pass4sure download | pass4surekey | pass4sure cap | pass4sure free | examsoft | examsoft login | exams | exams free | examsolutions | exams4pilots | examsoft download | exams questions | examslocal | exams practice |

    www.pass4surez.com | www.killcerts.com | www.search4exams.com | http://www.radionaves.com/